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Riassunto 
Streptoccoccus pneumoniae (o pneumococco) è un batterio Gram-positivo in grado 
di colonizzare asintomaticamente il tratto nasofaringeo di più del 60% dei bambini e 
del 30% degli adulti, ma è anche annoverato tra i più importanti patogeni umani se si 
considerano il tasso di mortalità e morbilità ad esso associati su scala mondiale 
(circa un milione e mezzo di morti ogni anno tra i bambini di età inferiore a 5 anni). 
Pneumococco è, infatti, l’agente eziologico maggiormente associato alle polmoniti 
contratte in comunità, ma è anche causa di infezioni invasive e non invasive quali 
sinusite, otite media, meningite, batteriemia, endocarditi e pericarditi. Le categorie di 
età maggiormente colpite da infezioni da pneumococco sono i bambini al di sotto dei 
2 anni di età e gli anziani (>65 anni) con un andamento di incidenza annuale che 
segue più o meno quello dell’influenza stagionale. Quali siano i meccanismi 
molecolari e i fattori di virulenza che permettono/favoriscono la transizione da uno 
stato di semplice colonizzatore a quello di patogeno non sono stati ancora 
completamente chiariti e sono oggetto di studi epidemiologici e biomolecolari.  
Le malattie da pneumococco sono in generale efficacemente trattabili con penicillina, 
trimetoprim o macrolidi, tuttavia la diffusione delle resistenze agli antibiotici ha reso 
necessaria un’effettiva strategia di prevenzione che possa diminuire la rapidità e la 
diffusione delle infezioni. Il modo più immediato ed efficace per raggiungere questo 
scopo è una vaccinazione di massa con un vaccino basato su componenti batteriche 
(polisaccaridi capsulari o proteine superficiali) in grado di prevenire l’infezione 
causata da tutti gli isolati di S. pneumoniae. 
Il disegno di un vaccino polisaccaridico che abbia una copertura globale è reso 
complicato da fattori quali l’elevata eterogeneità della capsula (94 sierotipi capsulari), 
l’eterogenea distribuzione geografica dei vari tipi capsulari e la capacità dello 
pneumococco di acquisire nuovi tratti fenotipici attraverso un meccanismo di 
trasformazione naturale che lo rende geneticamente flessibile e soggetto a frequenti 
ricombinazioni generanti mosaicismo genetico. In particolare, quando tali eventi di 
ricombinazione avvengono a livello del locus dell’operone della capsula (fenomeno 
noto in letteratura come capsular switching) in risposta alla presenza di un elevato 
quantitativo di anticorpi contro un determinato sierotipo capsulare, il microrganismo 
diventa capace di sfuggire al sistema immunitario.  
Ad oggi sono già presenti sul mercato vaccini a base polisaccaridica (Pneumovax 
23) e vaccini polisaccaridici coniugati (Prevenar7, Prevenar13, Synflorix); questi 
ultimi sono immunogenici anche nei bambini al di sotto dei due anni. Sebbene questi 
vaccini abbiano dimostrato una buona efficacia nel ridurre i casi di malattia invasiva 
causata da S. pneumoniae, il loro uso è limitato dal fatto che inducono un’immunità 
sierotipo-specifica e pertanto sono in grado di proteggere efficacemente solo contro 
le malattie invasive causate dai sierotipi contenuti nel vaccino stesso. Questo implica 
che, in base alla diversa distribuzione dei sierotipi, i vaccini polisaccaridici in 
commercio possono avere un grado di copertura diverso a seconda della regione 
esaminata. Un ulteriore fattore da tenere in considerazione per quanto riguarda la 
copertura del vaccino è il fatto che nei paesi in cui è stata introdotta la vaccinazione, 
è stato evidenziato un certo grado di redistribuzione dei sierotipi, associato ad un 
aumento della diffusione di quelli non coperti dal vaccino stesso, fenomeno noto in 
letteratura come serotype replacement. 
L’alternativa concreta per ampliare la copertura di un vaccino e superare i problemi di 
serotype replacement potrebbe essere quella di sviluppare un vaccino sierotipo 
indipendente, basato su proteine di superficie conservate. Per S. pneumoniae, sono 
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note più di 100 proteine superficiali, molte delle quali sono fattori di virulenza o 
giocano comunque un ruolo importante nella patogenesi. Tuttavia, la variabilità 
genetica di tali proteine, i loro profili di espressione, e come queste possano 
determinare il tropismo tissutale, l’invasività e lo sviluppo della malattia, sono degli 
aspetti che, seppur investigati estensivamente, sono ancora poco conosciuti. 
Tra le proteine selezionate recentemente come potenziali antigeni vi sono le subunità 
che costituiscono il pilo-1, una struttura fibrillare identificata sulla superficie di alcuni 
ceppi di S. pneumoniae. Questi ceppi contengono nel loro DNA genomico un 
elemento genetico di 12Kb noto come pilus islet -1 (PI-1), contenente 7 geni 
codificanti per: le tre subunità strutturali del pilo (la subunità principale RrgB e due 
proteine ancillari RrgA ed RrgC); un regolatore trascrizionale positivo (RlrA); e tre 
transpeptidasi o sortasi (SrtC-1, StrC-2, SrtC-3), enzimi in grado di assemblare 
covalentemente le tre subunità strutturali e di ancorare il pilo alla parete batterica.  
La dimostrazione che il pilo contribuisce alla virulenza batterica e favorisce 
l’adesione alle cellulle dell’epitelio dell’ospite, unita all’evidenza che l’immunizzazione 
con le diverse subunità (espresse in forma ricombinante) è protettiva in un modello 
animale di infezione intraperitoneale, ne fanno un potenziale candidato per un 
vaccino. In particolare, la subunità strutturale più abbondante del pilo (RrgB), nonché 
la più protettiva, è considerata il principale candidato per un vaccino a base proteica 
contro lo pneumococco. Questa proteina, ben caratterizzata dal punto di vista 
strutturale, è conosciuta in tre diverse varianti (note come clade I, II e III) con un 
grado di omologia nella sequenza proteica compresa tra il 48 e il 60%. Dato questo 
basso grado di omologia, le tre varianti di RrgB inducono una risposta immunitaria 
variante-specifica non in grado di assicurare una cross- protezione tra ceppi che 
esprimono pili con RrgB di varianti diverse. Al fine di ampliare la copertura di un 
vaccino contenente il candidato RrgB a tutti i ceppi di pneumococco che possiedono 
PI-1 (e quindi con ogni probabilità esprimono il pilo-1 sulla loro superficie), è stata 
generata una proteina di fusione (RrgB321) contenente le tre varianti di RrgB legate 
covalentemente testa-coda. RrgB321, in animali immunizzati, è in grado di stimolare 
la produzione di anticorpi contro le tre varianti di RrgB in maniera equivalente e di 
proteggere efficacemente contro infezioni causate da ceppi piliati di S. pneumoniae 
(contro ceppi rappresentativi delle tre varianti).  
Il lavoro di tesi di questi tre anni ha avuto due obiettivi principali, entrambi volti ad 
una migliore caratterizzazione del candidato per il vaccino RrgB e, più in generale del 
pilo-1, quale determinante antigenico:  
 
1- Caratterizzare l’espressione di RrgB e degli altri componenti del pilo-1, 
cercando di identificare i determinanti molecolari che ne favoriscano 
l’espressione; 
 
2- Verificare come l’espressione del pilo possa influenzare la protezione indotta 
dalla vaccinazione con RrgB321.  
 
In merito al primo obiettivo sono stati condotti esperimenti volti a chiarire il ruolo ed 
analizzare l’espressione di tutte le proteine costituenti il pilo e in particolare di RrgB. 
In dettaglio, l’espressione del pilo è stata valutata mediante FACS (Fluorescence-
activated cell sorting), microscopia a immunofluorescenza e Western blot. Le analisi 
condotte su differenti ceppi contenenti PI-1 hanno rivelato che, diversamente da 
quanto visto per altri antigeni, in ogni ceppo è sempre possibile individuare due 
sottopopolazioni batteriche, una esprimente e l’altra non esprimente il pilo. Le due 
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sottopopolazioni coesistono nelle condizioni analizzate in vitro, in proporzioni variabili 
a seconda del ceppo analizzato e tali da non essere correlabili nè con il sierotipo o 
con il genotipo del ceppo stesso, né con la variante di RrgB espressa. Utilizzando le 
medesime metodiche è stato possibile dimostrare che quando il pilo è presente sulla 
superficie, anche tutti gli altri componenti codificati da PI-1 sono espressi (viceversa 
quando il pilo non è presente gli altri geni non sono espressi), indicando che 
l’espressione del pilo è finemente regolata tramite un meccanismo di tipo on-off. 
Allo scopo di identificare eventuali condizioni o stimoli ambientali in grado di 
modulare il grado di espressione del pilo ed in particolare di aumentare la 
percentuale di batteri che lo esprimono, diversi ceppi di S. pneumoniae sono stati 
cresciuti in differenti condizioni di coltura e l’espressione del pilo è stata poi 
analizzata mediante FACS. In particolare, sono stati analizzati: a) diverse fasi di 
crescita batterica; b) diversi terreni di coltura (solidi oppure liquidi, terreni ricchi –
THYE, BHI, RPMI- e un terreno minimo); c) diversi valori di pH (5.5; 6.4; 8.4); d) 
differenti quantità di ossigeno (condizioni atmosferiche e 5% CO2). È stato inoltre 
valutato se l’aggiunta di metalli quali ferro e manganese (MnSO4, FeCl3) o di siero 
(FBS) al terreno di coltura potesse avere un effetto sull’espressione del pilo. Allo 
stesso modo è stata analizzata l’espressione del pilo dopo crescita in presenza di 
cellule epiteliali umane o con supernatanti di coltura provenienti da colture cellulari. 
Infine è stata valutata la percentuale di batteri esprimenti RrgB in presenza di 5 o 
10% di sangue (montone o coniglio) in coltura liquida. Nessuna delle molteplici 
condizioni analizzate in diversi ceppi si è dimostrata in grado di modificare la 
percentuale di batteri non esprimenti il pilo a vantaggio di quella esprimente, o 
viceversa. L’unica condizione capace di contribuire positivamente all’espressione del 
pilo è stata la crescita in presenza di sangue. Tuttavia, data la notevole variabilità 
sperimentale dei risultati ottenuti nei diversi ceppi analizzati, non è possibile 
affermare in maniera univoca che la presenza di sangue nel terreno di coltura sia in 
grado di stimolare l’espressione del pilo.  
Per poter meglio caratterizzare e cercare di individuare i determinanti che sono alla 
base dell’ espressione differenziale all’interno di una popolazione dello stesso ceppo 
sono state individuate e successivamente separate colonie con un diverso grado di 
espressione del pilo. Mediante Colony blot (Western blot su singole colonie) e 
passaggi successivi di selezione e ricrescita è stato possibile isolare, per 6 diversi 
ceppi, due sottopopolazioni arricchite in batteri esprimenti (High) e non esprimenti il 
pilo (Low). Le due sottopopolazioni arricchite sono risultate stabili in coltura in vitro 
(anche in seguito a diversi passaggi consecutivi su piastra) ma non è stato possibile 
ottenere una popolazione omogenea per l’espressione del pilo (100% dei batteri 
esprimenti o non esprimenti). I profili di espressione delle due sottopopolazioni 
arricchite (H ed L) sono stati confrontati tramite expression profile microarray per 
cinque diversi ceppi (utilizzando RNA totale da coltura in vitro) al fine di individuare 
eventuali determinati genetici deputati o che contribuiscono alla regolazione 
dell’espressione del pilo. Dal confronto dei livelli di RNA tra la popolazione H ed L 
dello stesso ceppo, risulta che l’espressione di tutte le proteine codificate da PI-1 
(incluso il regolatore positivo rlrA) sono regolate a livello trascrizionale. I livelli di RNA 
di tutti i componenti dell’isola risultano infatti significativamente più alti nelle 
popolazioni esprimenti il pilo. I dati ottenuti, confermati anche da real-time PCR, 
suggeriscono inoltre, come già proposto in precedenti lavori, la presenza di più di un 
promotore all’interno dell’isola, dal momento che i livelli di RNA delle subunità 
strutturali risultano significativamente più alti di quelli delle sortasi (enzimi deputati 
all’assemblaggio). L’analisi poi dell’intero dataset, attraverso il confronto dei livelli di 
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RNA degli altri geni esterni all’isola per le due sottopopolazioni non ha evidenziato 
altre differenze significative che fossero indice di un coinvolgimento di altri geni nella 
regolazione dell’espressione del pilo. Tale osservazione risulta in disaccordo con 
alcune recenti pubblicazioni che descrivono diversi regolatori negativi del pilo, la cui 
assenza, sembrerebbe in grado di stimolarne l’espressione.  
Al fine di meglio caratterizzare la regolazione dell’espressione ed, in particolare, di 
dimostrare che l’espressione del regolatore positivo RlrA è sufficente ad indurre la 
trascrizione e la polimerizzazione di tutti i componenti del pilo, sono stati generati 
plasmidi per l’espressione costitutiva del regolatore positivo (RlrA), della proteina 
strutturale RrgB e di una delle sortasi necessarie all’assemblaggio (SrtC -2). Tali 
plasmidi sono stati utilizzati per trasformare la popolazione L di un ceppo e verificare 
poi tramite Western blot e microscopia a immunofluorescenza l’espressione dei 
singoli componenti del pilo e del loro assemblaggio sulla superficie batterica. I 
risultati hanno dimostrato che l’espressione costitutiva di SrtC-2 e di RrgB non ha 
alcun effetto sulla polimerizzazione o sull’espressione degli altri componenti 
dell’isola. Al contrario, quando nella popolazione L si ha l’espressione costitutiva di 
RlrA, il 100% della popolazione batterica presenta il pilo sulla propria superficie. Ciò 
indica che l’espressione di RlrA, differentemente da RrgB e SrtC-2, è sufficiente ad 
indurre l’espressione di tutti i componenti dell’isola, permettendo così l’assemblaggio 
del pilo sulla superficie di tutta la popolazione batterica.  
I risultati ottenuti sopra descritti indicano che l’espressione del pilo cambia in risposta 
a stimoli che agiscono attivando l’espressione del regolatore RlrA. Nonostatante 
siano state analizzate molteplici condizioni di coltura in vitro non è stato possibile 
individuare quali siano questi stimoli e se essi agiscano direttamente o indirettamente 
modulando l’espressione del regolatore positivo.  
Tuttavia, la scoperta che l’espressione del pilo è bifasica ha portato alla necessità di 
valutare l’espressione del pilo durante l’infezione per capire se le condizioni in vivo 
siano in grado di modulare il rapporto tra batteri esprimenti e non esprimenti il pilo 
all’interno di una stessa popolazione, o se, per ragioni ancora sconosciute la 
presenza di una popolazione eterogenea per l’espressione del pilo possa costituire 
un vantaggio nelle diverse fasi di colonizzazione e sviluppo della malattia nei diversi 
tessuti dell’ospite. 
Per questi motivi, e per investigare ulteriormente l’efficacia protettiva di RrgB321 
sono stati condotti esperimenti utilizzando un saggio di opsono-fagocitosi in vitro ed 
un modello di infezione animale murino, monitorando il grado di espressione ad inizio 
e fine esperimento.  
I saggi di opsono-fagocitosi (OPA) permettono di misurare la funzionalità degli 
anticorpi generati dall’immunizzazione con l’antigene, verificando la loro capacità di 
mediare, in presenza di proteine del complemento, la fagocitosi/uccisione dei batteri 
da parte dei macrofagi, mimando così uno dei meccanismi che il nostro sistema 
immunitario utilizza per difendersi dalle infezioni. Saggi di OPA, condotti utilizzando 
le due sottopoplazioni arricchite in batteri esprimenti e non esprimenti il pilo (H e L) di 
un particolare ceppo, hanno dimostrato che l’attività fagocitica osservata in presenza 
di siero anti-RrgB321 dipende dalla proporzione di batteri esprimenti il pilo all’interno 
della popolazione. Infatti, la presenza di siero anti-RrgB321 induce la fagocitosi 
soltanto nella popolazione H in proporzione dipendente dalla concentrazione di siero 
utilizzato; al contrario non si osserva fagocitosi, anche ad alte concentrazioni di siero, 
per la popolazione L. Analisi al FACS, condotte sui batteri della popolazione H 
sopravvissuti al saggio di OPA, hanno inoltre dimostrato che la percentuale di batteri 
non esprimenti aumenta all’aumentare della concentrazione di siero utilizzato per il  
Riassunto 
 
7 
 
saggio di opsono-fagocitosi, dimostrando ulteriormente la fagocitosi selettiva 
anticorpo-mediata. 
Per verificare che i risultati ottenuti fossero dovuti alla reale fagocitosi dei batteri e 
non ad un effetto di inibizione dell’espressione del pilo da parte del siero anti-
RrgB321 tre differenti ceppi di S. pneumoniae sono stati cresciuti in presenza di 
anticorpi contro l’RrgB ed è stata verificata la loro capacità di replicare per sette 
generazioni. L’espressione del pilo analizzata tramite FACS ha rivelato che la 
presenza del siero non è in grado di alterare la proporzione di batteri esprimenti in 
favore di quelli non esprimenti e vicecersa.  
Questi dati hanno confermato che l’aumento, proporzionale alla diluizione del siero 
utilizzato nell’OPA, dei batteri non esprimenti il pilo è soltanto causato dalla fagocitosi 
anticorpo-mediata dei batteri esprimenti il pilo.  
Dati i risultati ottenuti nei saggi di OPA si è voluto verificare se l’RrgB321 fosse in 
grado di proteggere da infezioni contro ceppi di S. pneumoniae indipendentemente 
dal loro grado di espressione del pilo. Per verificare tale ipotesi sono stati condotti 
esperimenti di immunizzazione passiva e attiva utilizzando diversi modelli di 
infezione murini.  
Negli esperimenti di immunizzazione passiva, animali trattati con sieri derivati da 
immunizzazione con RrgB321 sono stati infettati sia con la popolazione H che con la 
popolazione L di uno stesso ceppo. Seguendo il corso dell’infezione e l’andamento 
della mortalità ad esso associata, si è potuto costatare che animali immunizzati con 
siero anti RrgB321 sono significativamente protetti contro l’infezione effettuata con la 
popolazione H, ma hanno un buon grado di protezione anche se il ceppo infettante 
ha un livello di espressione del pilo pressoché irrilevabile (popolazione L) al 
momento dell’infezione. 
Allo stesso modo, gli esperimenti di immunizzazione attiva condotti vaccinando gli 
animali con RrgB321 hanno confermato che la proteina di fusione è in grado di 
proteggere contro le infezioni di ceppi di S. pneumoniae pressoché 
indipendentemente dal grado di espressione di quest’ultimo al momento 
dell’infezione. Infatti, sono stati osservati una significativa riduzione della batteriemia 
e un aumento della sopravvivenza negli animali immunizzati sia se infettati con la 
popolazione H sia se infettati con la popolazione L per tre differenti ceppi.  
I dati ottenuti indicano che in entrambi i modelli animali utilizzati la vaccinazione con 
RrgB321 è in grado di produrre una risposta immunitaria efficace anche quando vi è 
una piccola parte di batteri che esprimono il pilo al momento dell’infezione. Una 
possibile spiegazione può essere rintracciata nella natura bistabile dell’espressione 
del pilo. É infatti possibile che durante lo sviluppo della malattia le interazioni dei 
batteri con i tessuti dell’ospite inducano un cambiamento nello stato dell’espressione 
delle componenti batteriche, favorendo l’espressione del pilo in batteri prima non 
esprimenti, e che quindi, in animali immunizzati con RrgB, diventerebbero aggredibili 
dal sistema immunitario. Un’ipotesi alternativa è che durante l’infezione, l’uccisione di 
batteri esprimenti il pilo, a seguito dell’immunizzazione con RrgB321, potrebbe 
indurre l’espressione nei batteri prima non esprimenti per ri-stabilire quell’equilibrio 
tra batteri piliati e non che si mantiene anche in vitro in molteplici condizioni colturali 
differenti. Per verificare la veridicità di queste ipotesi, l’espressione del pilo è stata 
valutata tramite FACS nei batteri recuperati dal sito di infezione (sangue) in topi 
immunizzati e in topi non immunizzati. Per tutti e tre i ceppi su cui è stata condotta 
l’analisi e per tutti i gruppi analizzati si è potuto osservare che nel caso dell’infezione 
con la popolazione H, nei batteri recuperati dal sangue si è osservata una lieve 
diminuzione nella proporzione (10%) dei batteri esprimenti il pilo; al contrario, nel 
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caso dell’infezione con la popolazione L, i batteri recuperati dal sangue hanno 
mostrato un lieve aumento nella proporzione (10%) di batteri esprimenti il pilo. Ciò 
avvalora l’ipotesi che l’espressione del pilo di S. pneumoniae può essere modulata 
nell’ospite, pur tuttavia in maniera indipendente dall’immunizzazione dell’animale. 
Infatti, non è stata osservata nessuna differenza nell’espressione del pilo tra i batteri 
recuperati dal sangue nei topi immunizzati rispetto ai topi non immunizzati.  
In conclusione, il lavoro di tesi svolto ha permesso di caratterizzare l’espressione dei 
componenti del pilo-1 di Streptococcus pneumoniae, portando evidenze della sua 
natura bifasica. Allo stesso tempo è stato dimostrato che una proteina di fusione 
costituita dalle tre varianti della principale proteina strutturale costituente il pilo 
(RrgB321) è in grado di proteggere in maniera efficace da infezioni contro ceppi di 
pneumococco positivi per la presenza di PI-1 (codificante i componenti del pilo) 
indipendentemente dal grado di espressione dello stesso. Nonostante non sia stato 
possibile chiarire il meccanismo attraverso il quale ciò avvenga, i dati ottenuti 
supportano l’inclusione di RrgB321 in un vaccino a più componenti contro le infezioni 
da Streptococcus pneumoniae. 
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Summary 
 
Streptococcus pneumoniae (S. pneumoniae) is a Gram-positive commensal of the 
nasopharyngeal tract of both children and healthy adults. However, S. pneumoniae is 
also a leading cause of morbidity and mortality worldwide, being responsible for non-
invasive and invasive diseases such as acute otitis media, pneumonia, sepsis and 
meningitis. Despite the unquestionable efficacy of the available pneumococcal 
glycoconjugate vaccines, the limited coverage, along with the observed phenomenon 
of serotype replacement, could reduce their long-term effectiveness. For these 
reasons, the development of a serotype-independent vaccine relying on the use of 
surface-exposed protein antigens represents a valid alternative. In this context, 
pneumococcal pilus-1 components, and in particular the pilus backbone RrgB, 
demonstrated significant efficacy in protecting mice from lethal challenge.  
The S. pneumoniae pilus-1 is encoded by pilus islet 1 (PI-1), which has three clonal 
variants (clade I, II and III) and is present in about 30% of clinical pneumococcal 
isolates. Since a combination of the three RrgB variants could broad the efficacy of a 
pilus-based vaccine, a fusion protein (RrgB321) containing the three RrgB variants in 
a head to tail organization was constructed. It was recently reported that RrgB321 
elicites an antibody response against each of the variants and protectes mice against 
piliated pneumococcal strains of the three clades both by active and passive 
immunization, supporting the validity of this candidate as a potential antigen for the 
generation of a multi-component protein-based vaccine against S. pneumoniae.  
The data reported in this work contribute to the characterization of pilus-1 expression 
regulation in in vitro and in vivo experiments providing evidence that pilus expression 
is biphasic and demonstrating that the pilus expression level does not impair the 
protection induced by RrgB321 immunization in mouse models of infection.  
Analyzing the strains at the single-cell level, two phenotypically different sub-
populations of bacteria (one that expresses the pilus, while the other does not) could 
be identified. The proportions of these two phenotypes are variable among the 
strains tested and are not influenced by genotype, serotype, growth conditions, 
colony morphology or by the presence of antibodies directed toward the pilus 
components. Two sub-populations, enriched in pilus expressing or not expressing 
bacteria were obtained by means of colony selection and immuno-detection methods 
for five strains. PI-1 sequencing in the two sub-populations revealed the absence of 
mutations, thus indicating that the biphasic expression observed is not due to a 
genetic modification within PI-1. Microarray expression profile and western blot 
analyses on whole bacterial lysates performed comparing the two enriched sub-
populations, revealed that pilus expression is regulated at the transcriptional level 
(on/off regulation), and that there are no other genes, in addition to those encoded by 
PI-1, concurrently regulated across the strains tested. Moreover, evidence that the 
over-expression of the RrlA positive regulator is sufficient to induce pilus expression 
in pilus-1 negative bacteria, was reported. Overall the in vitro data presented suggest 
that the observed biphasic pilus expression phenotype is an example of bistability in 
pneumococcus. 
Additionally, in this study, the ability of RrgB321 antibodies to kill both H and L S. 
pneumoniae populations in the opsonophagocytosis assay, as well as the ability of 
RrgB321 to confer protection in vivo against both populations were analyzed.  
The results obtained demonstrate that: i) the opsonophagocytic killing mediated in 
vitro by RrgB321 antisera is strictly dependent on the pilus expression ratio of the 
strain used; ii) during the opsonophagocytosis assay pilus-expressing pneumococci 
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are selectively killed, and iii) no switch towards the pilus non-expressing phenotype 
can be observed. Furthermore, in sepsis and pneumonia models, mice immunized 
with RrgB321 are significantly protected against challenge with either the H or the L 
pilus-expressing population of strains representative of the three RrgB variants. This 
suggests that the pilus-1 expression is not down-regulated, and also that the 
expression of the pilus-1 could be up-regulated in vivo. In conclusion, these data 
provide evidence that RrgB321 is protective against PI-1 positive strains regardless 
of their pilus expression level, and support the rationale for the inclusion of this fusion 
protein into a multi-component protein-based pneumococcal vaccine. 
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Introduction 
 
Overview on Streptococcus pneumoniae and vaccine prevention of 
pneumococcal disease 
 
Streptococcus pneumoniae (pneumococcus) is a Gram-positive, alpha-hemolytic, 
bacterium isolated and described for the first time by George Miller Stenberg and 
Louis Pasteur, in 1881 [1,2]. (Figure 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  (A) Electron microscope photomicrograph of Streptococcus pneumoniae from 
MicrobeWiki and (B) negative stain TEM image showing a chain of S. pneumoniae TIGR4 
bacteria [3].  
 
 
Primarily a commensal, pneumococcus asymptomatically colonizes the nasopharynx 
of children and healthy adults. However, it is also a significant pathogen, able to 
spread from the site of carriage and to cause a range of infections such as otitis 
media, pneumonia, bacteremia and meningitis, especially in infants, ederly and 
immunocompromised persons [4,5]. The significance of S. pneumoniae as a human 
pathogen is highlighted by the estimate that in 2000 among children under 5 years of 
age were reported about 14.5 million episodes of serious pneumococcal disease with 
826000 deaths [6]. Other estimates report the pneumococcus to be responsible for a 
total of 1.6 million deaths annually [7]. However, invasive pneumococcal disease 
represents only a small fraction of all pneumococcal clinical syndromes, most of 
which are represented by nonbacteremic pneumonia (Figure 2). 
Many antibiotics such as doxycycline, fluoroquinolones and trimethoprim-
sulfamethoxazole have been used for the treatment of pneumococcal infections. 
However, antibiotic resistance has become a worldwide problem, limiting the choice 
of antimicrobial agents. Thus, the pneumococcus has been, and remains, a major 
cause of morbidity and mortality worldwide. 
A 
1 m 
B 
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Figure 2. Pneumococcal clinical syndromes. Modified from [8] 
 
 
For the prevention of the pneumococcal diseases, great efforts are being made to 
develop effective vaccines in both industrialized and developing countries. However, 
due to the complexity and the multiplicity of the S. pneumoniae isolates spread 
worldwide, none of the current vaccines can address the needs of both the elderly 
and children in all parts of the world. 
S. pneumoniae, in fact, produces a range of different colonization and virulence 
factors including the polysaccharide capsule, surface proteins and enzymes, and the 
pneumolysin toxin, that allow the bacterium to escape the host immune system and 
cause disease (Figure 3). 
The polysaccharide capsule is probably the most important pneumococcal virulence 
factor, as it protects the bacteria from phagocytosis; it is crucial for colonization, 
prevents mechanical removal by mucus [9] and can also restrict autolysis and reduce 
exposure to antibiotics [10]. Capsule polysaccharides are highly heterogeneous and, 
thus far, at least 93 different capsular serotypes have been described, according to 
their unique serological profiles and chemical structures [11-13]. 
Capsular serotyping, for historical reasons, is the most used and efficacious strategy 
for classification of pneumococcal strains; however, to better understand the 
population structure from the genetic point of view, a nucleotide sequence based 
method, Multi Locus Sequence Typing (MLST), has been developed in the last 
decade. The MLST involves the sequencing of internal fragments from seven house-
keeping genes (aroE, gdh, gki, recP, spi, xpt, ddl), and the unequivocal assignment of 
the isolates to a Sequence Type (ST) [14]. Moreover, through the algorithm eBURST 
single STs can be grouped in Clonal Complexes (CCs) based on the number of 
differences in their allelic profile [15,16], and sequence data can be held on a central 
database (http://www.mlst.net) and quired through a web server.  
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Figure 3. (A) Elettron microscopy analysis of a S. pneumoniae 6B strain showing the 
polysaccharide capsul; (B) Schematic rappresentation of S. pneumoniae virulence factors 
[17]. 
 
 
Since capsular polysaccharides (PS) are highly immunogenic and develop an 
immuno-response able to protect against infection caused by the homologous 
serotype, pneumococcal vaccines currently on the market are based upon serotype-
specific PS alone or conjugated with proteins.  
The 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23®, marketed by 
Merck & Company, Inc.) was licensed in the United States in 1983 and contains 23 
different capsular polysaccharides (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) [18]. This vaccine had a 
theoretical coverage of more than the 80% of the pneumococci causing infections in 
adults and children above 2 years of age. Unfortunately, the vaccine was less 
immunogenic in young children and immunocompromised patients [19] and showed 
efficacy only against bacteraemia and meningitis in the elderly population, but not 
against pneumonia, the most prevalent pneumococcal disease of this age group 
[20,21]. Furthermore, the PS vaccine is not effective against acute otitis media 
caused by S. pneumoniae [22] and does not induce a T cell-dependent immune 
response, thus limiting the period of protection because of the absence of memory B 
cells. Moreover, some capsule polysaccharides, including serotypes associated with 
penicillin resistance, are poorly immunogenic [23].  All these factors have led to the 
development of new pneumococcal vaccines containing polysaccharide antigens 
conjugated to carrier proteins, which are effective in developing an immune response 
also in children under 2 years of age and in reducing nasopharyngeal carriage of 
vaccine-type pneumococci [24,25].  However, no studies have shown improved 
efficacy and benefits of conjugate vaccines in the elderly [26]. The first conjugate 
vaccine (PCV-7 or Prevnar®), targeting seven serotypes (4, 6B, 9V, 14, 18C, 19F and 
23F), was approved for use in the United States in 2000 and subsequently adopted 
in many developed countries [27]. In 2009, a 10-valent vaccine, SynflorixTM (covering 
serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F), conjugated to Hemophilus 
A B 
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influenzae protein-D (PHiD-10), was approved in Europe. In 2010, a 13-valent 
conjugate vaccine covering serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F 
and 23F (PCV-13 or Prevnar-13) was approved in the United States for use among 
children aged from 6 weeks to 71 months and replaced PCV-7 [28]. (Figure 4) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Serotype composition of pneumococcal conjugate vaccines currently on the 
market. 
 
 
Unfortunately, these multi-valent vaccines only partially cover the diseases caused 
by S. pneumoniae serotypes circulating in developing countries, and the high 
manufacturing costs make them too expensive for the populations with the greatest 
need. Most importantly, events like serotype replacement induced by vaccination, 
and capsular switching (due to the horizontal transfer of the capsular loci from a 
strain to one other), have already been clearly demonstrated in several clinical and 
surveillance studies [29,30]. For this reason, the prospective vaccine failure has 
become a serious concern.  
Consequently, concerted global efforts are currently focused on developing 
alternative pneumococcal vaccine strategies. One of these approaches involves the 
development of vaccines based on pneumococcal proteins that contribute to 
pathogenesis and are common to all serotypes [31]. Such proteins, being T-cell-
dependent antigens, should be both highly immunogenic and able to elicit 
immunological memory in human infants [32]. Furthermore, proteins can be 
engineered for high-level expression at relatively low cost, and formulation is likely to 
be simpler, thereby making such vaccines more affordable for the developing 
countries. 
Pneumococci are estimated to express over 100 surface proteins, some of which are 
known to have a role in pathogenesis and virulence; however the function of the 
majority of them is still unknown [33]. Some of the surface proteins are currently 
under investigation as vaccine candidates such as: PspA and PspC (Choline-binding 
proteins); PsaA (metal-binding lipoprotein); PhtB and PhtE (poly-histidine triad 
proteins); NanA (neuraminidase) and other proteins that are covalently linked to the 
bacterial cell wall by a carboxy (C)-terminal sortase (LPXTG; in which X denotes any 
amino acid) motif [34]. Another well-studied protein that is secreted by all known 
clinical isolates of S. pneumoniae is Ply, the pneumolysin toxin. Although Ply is not a 
surface protein, it is an important virulence factor, belonging to the family of pore-
PCV-7 
(7-valent) 
PCV-13 
(13-valent) 
SynflorixTM  
(10-valent) 
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forming toxins synthesized by Gram-positive bacteria that can directly damage 
epithelial surfaces and reduce the migration of phagocytic PMNs [35]. The roles for 
these proteins in bacterial physiology and pathogenicity based on mutagenesis 
studies in in vitro experiments and in animal models of pneumococcal disease have 
summarized in Table 1. Although several of these antigens have been shown to be 
protective immunogens [36], thus far the high sequence variability of these antigens 
or their toxicity (pneumolysin) limit their use as vaccine candidates. Recently, the 
availability of the complete genome sequence of virulent and non-virulent isolates of 
S. pneumoniae (http://www.tigr.org) has provided new classes of potential protein 
antigens. The chromosome of over 2 million base pairs contains slightly more than 
2000 predicted protein coding regions; interestingly, about 30% of the open reading 
frames (ORFs) still remains un-annotated and displays unknown or hypothetical 
function [37,38]. 
 
 
Table 1. Role in bacterial physiology and pathogenicity of proteins that have been 
considered as vaccine candidates 
 
 
 
 
 
Therefore, in vivo and in vitro techniques that complement in silico genomic searches 
are playing a crucial role in the identification of the proteins that provide the greatest 
promise in terms of novelty and applicability.  
The recent discovery that Gram-positive pathogens possess long filamentous pilus-
like structures extending from the bacterial surface has opened a new area of 
research in the understanding of their function in pathogenesis and their role as 
protective antigens [49,50]. 
 
 
Pneumococcal 
proteins 
Main role in colonization and disease References 
Pneumolysin (Ply) 
Membrane pore forming cytolytic toxin that also activates 
complement 
[39] 
PspC (known as 
CbpA) 
Involved in adherence and colonization [40] 
PspA Complement inactivation [41] 
NanA, BgaA 
Cleavage of terminal sugars; revealing receptor for 
adherence, promoting Blood-Brain Barrier interaction 
[42] 
PavA binds to fibronectin [43] 
LytA digest the cell wall, which results in the release of ply [44] 
PsaA 
Metal ion transport involved in resistance to oxidative 
stress 
[45] 
Pilus-1 components Promote adherence, colonization and inflammation [46] 
PfbB mediates bacterial adhesion to human epithelil cells [47] 
PsrP 
mediates bacterial attachment to Keratin 1 and promotes 
the formation of large bacterial aggregates in the 
nasopharynx and lungs 
[48] 
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Streptococcus pneumoniae pili 
In S. pneumoniae strains, two unrelated pilus gene clusters, coding for two 
antigenically different pili, have been identified: pilus islet 1 (PI-1) and pilus islet 2 (PI-
2) [51,52] (Figure 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5. (A) Genomic organization of pilus-encoding islets in S. pneumoniae [51]. (B) 
Immunoelectron microscopy analysis of whole bacterial cells incubated with polyclonal 
antibodies (conjugated to 5-nm gold particles) raised against the backbone pilus proteins 
(RrgB and PitB).  
 
 
Both pili have the typical features of Gram-positive pili are composed of pilus 
backbone proteins covalently linked in a head-to-tail organization; have one or two 
additional (ancillary) proteins linked to the backbone structure and are assembled by 
specialized transpeptidases also referred to as sortases [49,53]. 
Each pilin subunit has a C-terminal cell wall sorting signal (CWSS), consisting of an 
LPXTG-like motif required for the covalent attachment to either the cell wall or to the 
flanking pilus subunits and a hydrophobic domain, followed by a stretch of basic 
amino acid residues. The covalent linkage of pilus subunits consists in an amide 
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bond between the side chain of a lysine residue and the threonine in the CWSS 
[50,54]. 
The PI-2, identified by Bagnoli et al. [51], is a 7-kb region located between the genes 
that encode the peptidase T (PepT) and ferrochelatase (HemH) and flanked by 
putative 7-bp (TCCTTTT) insertion sites. The PI-2 has been reported to be present in 
about the 16% of the isolates and prevalent in emerging, non-PCV7 serotypes 
[51,55]. The islet is composed of 5 genes, which are predicted to encode the two 
surface protein, PitA and PitB (with pitA a pseudogene due to a stop-codon), a signal 
peptidase-like protein (SipA), and 2 sortases (SrtG1 and SrtG2); SrtG2 is 
nonfunctional in most of the strains. Pilus-2 appears to consist solely of PitB 
polymers, and has been shown to mediate adhesion of S. pneumoniae to eukaryotic 
cells [51].  
The S. pneumoniae pilus-1 is encoded by a 12-kb genomic region (PI-1) and is also 
referred to as rlrA pathogenicity islet. This region is flanked by conserved mobile 
genetic elements characterized by direct inverse repeats, known as Insertion 
Sequence (IS) elements [46,49]. The PI-1 contains seven genes coding for: a Rof-A-
like transcriptional regulator (RlrA), which positively regulates pilus expression [56] 
and its own expression, three pilus structural subunits with LPXTG-type CWSSs 
(RrgA, RrgB and RrgC) and three sortase enzymes (SrtC-1, SrtC-2 and SrtC-3 also 
named SrtB, SrtC and SrtD respectively), which covalently assemble the pilus 
subunits on the bacterial surface [52,57-59] (Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Molecular architecture of S. pneumoniae pilus-1. (A, B) Negative stain TEM image 
showing the localization of the ancillary proteins RrgA and RrgC of TIGR4 pili. The white 
arrows indicate RrgA in panel A and RrgC in panel B. The black arrows point away from the 
bacterium. (C) Model of S. pneumoniae pilus. The symbols indicate the LPXTG motifs for 
each pilin: * YPRTG (RrgA), § IPQTG (RrgB), ¶ VPDTG (RrgC) and the pilin motif (#) [3]. 
20 nm
RrgA 
RrgB 
RrgC 
Cell wall/Peptidoglycan 
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In pilus-1, RrgB is the major subunit that forms the backbone of the structure, RrgA is 
the major ancillary protein, localized at the pilus tip and responsible for the host 
adhesion properties of the pilus, whereas RrgC is the minor ancillary protein, likely 
located at the pilus base and responsible for the putative cell wall anchoring [3,60,61]  
(Figure 6). 
PI-1 exists in three variants, namely clade I, II and III. Most of the gene variability is 
concentrated in the genes coding for the pilus components: rrgA and rrgB. In terms of 
protein sequence variability RrgB is classified into three variants (I, II and III), RrgA 
exists in two major groups (clades I and II) whereas RrgC and all the sortases are 
highly conserved [62] (Figure 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Genetic variability among the pilus-1 subunits. The protein sequence conservation 
between the clades (I, II, III) is reported in percentage for each pilin. 
 
 
The contribution to the pilus formation of the three sortases (srtC-1, srtC-2, srtC-3) 
has recently been reported [57]. The three sortases are redundant, as they are all 
able to polymerize the structural backbone (RrgB) as well as to link RrgA and RrgC to 
the pilus shaft. 
Considerable effort has been directed also to unravel the structure and the 
mechanisms of biogenesis of pilus-1. The crystal structures of the adhesin RrgA and 
of the major pilin RrgB were recently resolved [63,64], while no structure is available 
for the cell wall anchor protein RrgC. 
Despite molecular epidemiological reports highlight that PI-1 is present in about 30% 
of the pneumococcal isolates, regardless of the geographical origin and the disease 
outcome analyzed [62,65,66], several studies have already demonstrated the role of 
the pilus in virulence and host inflammatory responses. In detail, mutants lacking PI-1 
are impaired in adhesion to cultured epithelial cells (mostly due to RrgA) and are less 
virulent in murine models of colonization, pneumonia and invasive diseases [46,67]. 
Interestingly, immunization of mice with pilus structural antigens was shown to induce 
protection against lethal challenge by piliated strains. These studies indicate that 
vaccination with pilus subunits confers the same protection as vaccination with heat 
killed bacteria, supporting the possibility to use pilus antigens in a multivalent 
pneumococcal vaccine [68] (Figure 8). 
However, whether all PI-1 positive pneumococci express pili (in vitro and in vivo) and 
if genetic differences and growth conditions could influence pilus-1 expression levels 
was still not clear. 
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Moreover, while protection against invasive disease was demonstrated when pilus 
antigens were used as vaccines in mouse models, it was not yet reported if the level 
of the pilus expression could impair the protection against piliated pneumococci. 
 
 
 
 
 
 
 
 
 
Figure 8. Protective efficacies of pilus subunits in mice. Bacteremia at 24h postchallenge 
(TIGR4) of vaccinated mice are shown; ctrl indicates mice receiving only the corresponding 
adjuvant plus saline; * and ** indicate P values of <0.05 and <0.01, respectively (one-tailed 
Mann-Whitney U test), for comparison with the corresponding control groups [68]. 
 
For this reason, the focus of this work has been to characterize the expression of the 
pneumococcal pilus-1 using strains of clade I, II and III, both in in-vitro and in-vivo 
conditions.  
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Introduction 
Streptococcus pneumoniae pilus-1 is a virulence factor involved in adherence to host 
cells, and its components are able to protect against piliated strains. For this reason, 
pilus proteins are regarded as promising antigens of new generation protein-based 
vaccines. Considerable effort has been directed to unravel the structure, the 
mechanisms of biogenesis and the epidemiology of pilus-1. Moreover, several 
reports have focused on the evaluation of genetic regulators that are able to 
modulate pilus expression and therefore bacterial virulence. Seven proteins, in 
addition to the PI-1 positive regulator RlrA, were demonstrated by different groups to 
negatively influence in vitro pilus expression levels (MgrA, HK343, MerR, CbpS, 
TCS08, mntE, PsaR) [67,69-71].  
Despite a significant increase in pilus prevalence was recently observed, suggesting 
that the pilus confers important selective advantages in colonization, its prevalence in 
all population does not exceed the 30% [72]. This potential fitness advantage led us 
to further investigate the mechanism of regulation of pilus expression in 
pneumococcus.  
Indeed, gene expression in bacteria is traditionally studied as the average behaviour 
of cells in a population, with the assumption that under a particular set of conditions 
all cells express genes in an approximately uniform manner. However, the advent of 
techniques that facilitate the investigation of individual cell behaviour has  revealed 
that, within isogenic populations, bacterial cells can display heterogenous 
phenotypes. These mechanisms, used by several bacterial species to generate intra-
population diversity, increase bacterial fitness and are important in niche adaptation, 
or to escape host defenses [73].  
Various processes can contribute to this variability within a bacterial population and 
can be based on genetic rearrangement (phase variation) or can be epigenetic in 
nature and not be accompanied by changes in DNA sequence (phenotypic variation).  
Phase variation in many bacterial species is often mediated by frequent and 
reversible changes in the lengths of short DNA sequence repeats (termed 
microsatellites) located in protein-coding regions or upstream regulatory regions, 
leading to deactivation or alteration of the associated genes [73]. Phase variation 
events can also be due to DNA rearrangements of fragments up to several kilobases, 
such as: i) homologous recombination occurring between a silent allele of a gene and 
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the gene located at the expression site; ii) site-specific recombination events caused 
by inversion, insertion or excision/transposition of a DNA region [74]; iii) duplication 
events as is the case of the genes involved in the capsular biosynthesis in some 
serotypes of S. pneumoniae  [75]. Otherwise, epigenetic regulation of phenotypic 
variation occurs in the absence of a change in DNA and can involve differentially 
methylated sequences in the regulatory regions of the phase-varying gene or operon. 
Some epigenetic traits can also depend on the presence of positive or double-
negative feedback loops in the regulatory network that determine the activity of key 
regulators, generating multistable bacterial populations. Phenotypic variation based 
on this type of network architecture is known as bistability and is characterized by the 
existence of two (or more) distinct phenotypes within an isogenic population [76]. 
Indeed, bistability occurs when in a bacterial cell the expression level of a gene 
comes through a threshold and the quantitative change becomes qualitative with the 
coming out of a new pattern of gene expression and the splitting of the bacterial 
population into coexisting cell types. This regulation system implies that it is possible 
to switch between two alternative states but not to rest at an intermediate state [77].  
Two mechanisms have been proposed to drive this kind of bifurcation. The first 
mechanism requires that the master gene is positively auto-regulated and establish a 
positive feedback loop. A second mechanism is a double-negative regulatory circuit 
involving the mutual repression of two repressors (Figure. 1.1). 
 
 
 
 
 
 
 
 
 
 
Figure. 1.1 Two network configurations that lead to bistable expression. The first involves a 
positive transcriptional autoregulatory loop together with cooperativity in promoter activation. 
The second involves two mutual repressing repressors. An inducer antagonizes the action of 
repressor 1, throwing the switch in the direction of derepression of target genes under the 
control of repressor 2. Open symbols denote repressors and closed circles denote activators 
Modified from [77]. 
 
 
Bistability may provide a selective advantage for subsets of bacteria under adverse 
conditions and has been described in many different organisms (i.e. competence 
development in Bacillus. subtilis and also in Streptococcus. pneumoniae) [74,78]. In 
addition, a bistable expression was already demonstrated for the Ebp-type pili in 
Enterococcus faecalis [79] and for the FCT-3 pili in Streptococcus pyogenes [80].  
Furthermore, regulation of gene expression allows the bacterium to be optimally 
suited to its growth environment. Thus, the expression of phase-variable genes 
would also be under environmental control. Iron starvation, for example, increases 
the frequency of antigenic and phase variation of Neisseria gonorrhoeae pili [81], and 
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stimuli such as temperature, pH, carbon source and amino-acid concentration affect 
the expression of phase-variable pili in Escherichia coli and Salmonella enterica 
[82,83]. 
Herein, given the implication that the S. pneumoniae pilus-1 might have in disease 
development, pilus expression was characterized at the single-cell level and under 
different growth conditions, providing evidence of its bistable nature. 
 
 
 
Results 
Pilus-1 has a biphasic expression pattern 
In order to elucidate pilus expression in S. pneumoniae, bacteria of a serotype 4 
strain (TIGR4) were grown in liquid culture, stained with antibodies raised against the 
pilus components (RrgA, RrgB, and RrgC) and three surface exposed proteins 
(PspC, PhtA and BgaA), and then analyzed by flow cytometry (FACS) [84-87] (Figure 
1.2A).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Pilus components display a biphasic expression pattern. A) TIGR4 bacteria 
were labeled with anti-RrgA, RrgB clade I, RrgC, BgaA (beta-galactosidase), PhtA (pneumococcal 
histidine triad protein A) or PspC (pneumococcal surface protein C) primary antibodies (1:400 dilution), 
and with FITC anti-mouse IgG secondary antibodies (1:100 dilution). Bacterial staining was analyzed 
by flow cytometry (FACS-Calibur). Sera of mice immunized with PBS were used as negative control. 
B,C) TIGR4 bacteria were processed for immunofluorescence, stained with mouse anti-RrgB 
antibodies (1:2000 dilution) (red) and with S. pneumoniae anti-capsular antibodies (Omniserum 
1:2000 dilution) (green). Imaging was performed with a confocal microscope.  
 
While the bacteria were found to uniformly express PspC, PhtA and BgaA, the 
specific antibodies for RrgA and RrgB revealed the presence of two sub-populations, 
one expressing high levels of the pilus subunits (Pil+), while the other displayed a 
mean fluorescence intensity (MFI) comparable to the negative control (sera raised 
against an unrelated protein) (Pil-). Interestingly, the analysis of bacteria labeled with 
anti-RrgC antibodies revealed a single homogeneous population with an MFI similar 
to the negative control, confirming that, in intact bacteria, RrgC is not exposed on the 
bacterial surface [3]. To support the data obtained by flow cytometry, the bacteria 
4 m 
4 m 
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were incubated with the antisera and then analyzed by immunofluorescence. As 
shown in Figure 1.2B (and in the enlargement of Figure 1.2C), bacteria were 
uniformly stained by anti-capsular antibodies, whereas the RrgB pilus specific signal 
was present only in a subset of bacteria (Pil+) and undetectable in the others (Pil-).  
 
S. pneumoniae pilus expression is not correlated with genotype, clade type 
and serotype 
A worldwide collection of 1366 strains of S. pneumoniae (Figure 1.3) including both 
carriage, AOM (acute otitis media) and invasive clinical isolates from different 
geographical origins, were characterized for serotype (with conventional methods) 
and sequence type (ST), for the presence of the PI-1 and for PI-1 clade. Multi Locus 
Sequence Typing (MLST), Clonal Complex (CC) assignment by E-BURST analysis, 
and PI-1 detection were performed as previously described [62].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Composition of the Novartis S. pneumoniae global collection. Geographical 
origin, number of strains and disease outcome are indicated (ID: invasive disease, C: 
carriage, AOM: acute otitis media). 
 
 
Given the biphasic expression pattern observed in the TIGR4 strain, a panel of 139 
S. pneumoniae strains, randomly selected among those that resulted PI-1 positive 
within the entire collection (436), were analyzed for pilus-1 expression by FACS 
analysis. All of the selected strains revealed a biphasic pilus expression, with the 
proportion of Pil+ bacteria ranging from 5 to 95%. As presented in Figure 1.4 for a 
selection of strains, there was no correlation between the ratio of Pil+ versus Pil- 
bacteria (pilus expression ratio) and the genotype, clade type and serotype. In 
addition, there was no association with the disease outcome of the isolates, as the 
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pilus expression ratio was heterogeneous in invasive, carriage and otitis media 
strains from the same or different geographical origins (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Pilus expression ratio is not correlated with serotype, genotype or clade 
type. Bacteria containing either PI-1 clade I (A), clade II (B) or clade III (C), were labeled with clade 
specific anti-RrgB antibodies (1:400 dilution) and FITC anti-mouse IgG secondary antibodies (1:100 
dilution). Pilus-1 expression was then analyzed by flow cytometry (FACS-Calibur).  
 
 
A detailed analysis of the PI-1 sequence revealed the presence of variable short 
nucleotide repeats in the intergenic regions upstream RrgA (2-6 CTATA repeats) and 
RrgB (poly-A tract containing 5 or 6 adenosine nucleotides). Since in other organisms 
the presence of different repeat numbers in the promoter region accounts for variable 
expression of the downstream gene [88-90], we hypothesized that these sequence 
repeats could act as regulation signals for RrgA and RrgB-RrgC expression. 
However, we found no correlation between the number of repeats and the pilus 
expression ratio in the 44 strains analyzed [91] (data not shown). 
 
Pilus expression ratio remains unchanged growing the bacteria under different 
conditions  
The identification of factors able to modulate pilus-1 expression in vitro, and, in 
particular, to enhance the pilus expression ratio could facilitate the understanding of 
the pilus role in vivo. Therefore, three S. pneumoniae strains (TIGR4, 6B Finland 12 
and 35B SME 15) were grown under several growth conditions and pilus-1 
expression was evaluated by flow cytometry.  
In detail, pilus expression analysis was performed on bacteria grown in rich media 
(THYE, Tryptic Soy Broth, Brain Hearth Infusion broth) and in a chemically defined 
minimal medium (CDM) [92] alone or supplemented with MnSO4 (1 mM), FeCl3 (≥ 50 
mM) or Fetal Bovine Serum (20%). Bacteria were also grown until different growth 
phases (A600 ranging from 0.1 to 1.2) (Figure 1.5), at different pH values (5.5, 6.4, 
8.4) or in the presence of different O2 concentrations (air condition or 5% CO2). 
In all the conditions tested the analyses performed by using flow cytometry revealed 
that pilus-1 expression remained unchanged. 
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Figure 1.5. Pilus expression ratio is constant at different growth phases. Bacteria 
expressing pilus-1 of clade I (A, TIGR4), clade II (B, 6B Finland 12) or clade III (C, 35B 
SME15) were grown in THYE at different A600 (0.02, 0.1, 0.25, 0.5 and 1) and labeled with 
clade specific anti-RrgB antibodies (1:400 dilution), and FITC anti-mouse IgG secondary 
antibodies (1:100 dilution). Pilus-1 expression was then analyzed by flow cytometry (FACS-
Calibur). 
 
 
Only the addition of 5-10% fresh sheep blood to CDM medium increased the pilus-1 
expression ratio to variable extents in TIGR4. As shown in Figure 1.6, when TIGR 4 
bacteria were grown in presence of blood and than analyzed by flow cytometry, the 
proportion of Pil+ bacteria increase of about 30% with respect to the control (bacteria 
grown in the absence of blood), with the consequent detriment of the Pil- bacteria. 
The increase observed in wild-type TIGR4 was not reproducible in the other two 
strains.  
 
 
 
 
 
 
 
 
 
 
Figure 1.6. TIGR4 pilus-1 expression increases in presence of blood. TIGR4 bacteria 
were grown in CDM alone (blue line) or supplemented with 10% sheep blood (green line) 
until A600 0.25 (mid log phase) and labeled with clade specific anti-RrgB antibodies (1:400 
dilution) and FITC anti-mouse IgG secondary antibodies (1:100 dilution). Pilus-1 expression 
was then analyzed by flow cytometry. 
 
 
Two S. pneumoniae sub-populations enriched in Pil+ or Pil- bacteria can be 
separated by colony selection 
In order to verify if Pil+ and Pil- bacteria after duplication maintain their original pilus 
expression phenotype, bacteria, following a sonication step, were grown on a plate 
as single colonies and then analyzed for pilus expression. As shown in Figure 1.7A, 
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when colony blot was performed with anti-RrgB antibodies, the colonies displayed 
different RrgB intensities, but none were RrgB negative.  
Colonies showing differential RrgB staining were selected and re-grown. Analysis 
performed by flow cytometry revealed that the majority of the colonies gave rise to 
populations with a ratio of pilus expression similar to the original strain. However, 
some colonies gave rise to either mostly Pil+ or Pil- sub-populations, defined as H 
(high pilus expression) or L (low pilus expression) sub-populations (Figure 1.7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Stable separation of enriched high (H) and low (L) pilus-1 expressing sub-
populations. A) TIGR4 pilus-1 expression was revealed on single colonies by colony 
immunoblot using anti-RrgB clade I antibodies (green, red and black circles correspond to 
colonies displaying low, medium or high RrgB specific signal intensities, respectively). 
Bacteria recovered from the growth of different colonies were stained with anti-RrgB clade I 
antibodies and analyzed by flow cytometry (B). The bacteria expressing (Pil+) and non- 
expressing (Pil-) the pilus-1 are indicated in the L (green) and H (red) enriched sub-
populations, and in the wt (black). H and L sub-populations were stained for 
immunofluorescence (C and D). Bacteria were incubated with mouse anti-RrgB antibodies 
(1:2000 dilution) (red) and with S.pneumoniae anti-capsular antibodies (Omniserum 1:2000 
dilution) (green). Imaging was performed with a confocal microscope. 
 
 
Despite numerous attempts, completely positive or negative sub-populations were 
never obtained, as there were always Pil+ and Pil- in the L and H sub-populations, 
respectively (Figure 1.7C and 1.7D). Notably, the two enriched sub-populations (H 
5 m 5 m 
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and L) were stably maintained after consecutive re-growths and long-term storage at 
-80°C.  
 
PI-1 components expression is undetectable in pilus-1 negative bacteria  
The S. pneumoniae pilus-1 polymerization is a complex and tightly coordinated 
process, not yet fully elucidated, requiring the simultaneous involvement of pilus 
components and bacterial sortases [57,93,94]. Following this observation, and in 
order to gain more insight into the pilus polymerization mechanism, the expression 
levels of the single PI-1 components were evaluated in Pil- bacteria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8. PI-1 encoded proteins are not expressed in RrgB negative bacteria. Western 
Blot analysis performed on whole bacterial lysates of TIGR4 H (H), L (L) or TIGR4 L depleted 
of RrgB positive bacteria (D), using polyclonal mouse antisera against RrgA, RrgB, RrgC 
(see High molecular weight ladders), SrtC-1, SrtC-2 ,SrtC-3 (see bands indicated by arrows) 
and SrtA (used as loading control).  
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In this regard, whole bacterial lysates of the TIGR4H and TIGR4L sub-populations, 
along with a TIGR4L sub-population further depleted of pilus positive bacteria (TIGR4 
D) (see materials and methods) were probed with antibodies raised against RrgA, B 
and C and SrtC1, 2 and 3; antibodies raised against the SrtA, a transpeptidase not 
involved in pilus assembly, are used as experimental control. As reported in Figure 
1.8, the impossibility to detect RrgA and RrgB on the surface of bacteria correlates 
with the lack of expression of all PI-1 components, both pilus-1 subunits and PI-1 
sortases as demonstrated by the absence of both the typical pilus High Molecular 
Weight (HMW) ladder and protein monomers in TIGR4 D. 
 
Biphasic pilus expression is not due to phase variation within the PI-1 
To exclude that the biphasic pilus expression pattern was due to phase variation 
events at the level of the positive regulator (rlrA), or, more in general, to point 
mutations within PI-1, the islet was sequenced for three strains (TIGR4, 
19FTaiwan14, OREP4) in the two enriched sub-populations (L and H) and in the 
wild-type. Neither alterations in the genomic sequence nor uncertainties in the 
chromatograms were observed, indicating that phase variation events within PI-1 are 
not responsible for the pilus-1 expression pattern. 
 
Only PI-1 components are differentially regulated between the H and L pilus 
expressing sub-populations 
To evaluate if pilus-1 expression was regulated at the transcriptional or translational 
level, total RNAs were extracted from the H and L sub-populations of five strains, 
TIGR4, 19F Taiwan 14, OREP4 (Clade I), 6BFin12 (Clade II) and 35B SME 15 
(Clade III) (Figure 1.9). The expression profiles of the L versus the H pilus expressing 
sub-populations were directly compared by microarray analysis (see materials and 
methods). As shown in Figure 1.10A, the analysis of the log2 H/L signal intensity ratio 
curves for PI-1 components in the five strains revealed that all the PI-1 genes 
(including rlrA) were differentially regulated in all the strains tested. The different log2 
signal intensity ratios observed among the isolates clearly depends on the ability to 
enrich in Pil+ and Pil- the H and L sub-populations, respectively. The strains 6B 
Finland 12 and 35B SME 15 showed the lowest log2 H/L signal intensity ratio, and 
were the isolates with the least enriched sub-populations (Figure 1.9). 
 
 
 
 
 
 
 
 
 
Figure 1.9. Pilus-1 expression profile of the H and L sub-populations. High and low pilus 
expressing sub-populations of strains TIGR4 (Clade I), 19F Taiwan 14 (Clade I), OREP4 
(Clade I), 6B Finland 14 (Clade II) and 35B SME 15 (Clade III) were labeled with clade 
specific anti-RrgB antibodies (1:400 dilution) and FITC anti-mouse IgG secondary antibodies 
(1:100 dilution). Pilus-1 expression was then analyzed by flow cytometry (FACS-Calibur).  
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In addition, the log2 ratio expression levels measured for the three sortases were 
consistently lower with respect to the pilus components and the rlrA regulator (Figure 
1.10A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10. Pilus-1 expression is regulated at the transcriptional level. 
A) Log2 ratio values indicating the PI-1 genes differential expression in High vs. Low pilus 
expressing sub-populations in the five above mentioned strains, as measured by spotted 
DNA microarray analysis. The data are measures of relative gene expression during in vitro 
growth in liquid cultures. The values reported for each gene are the mean of all the spots and 
their replicates within the array and of two independent experiments (bars represent standard 
deviations). B) Absolute gene expression levels of PI-1 genes measured for TIGR4 high and 
low pilus expressing sub-populations by microarray hybridization. Absolute expression levels 
reported for each gene are the mean of all the spots and their replicates within the array and 
of two independent experiments (bars represent the obtained standard deviations).  
 
 
This result is dependent on the different absolute expression levels measured for the 
PI-1 genes both within the H and the L pilus expressing sub-populations (sortase 
absolute expression levels were about four-five times lower than pilus components) 
as reported in Figure 1.10B for the TIGR4 strain. This observation suggests the 
presence of multiple promoters within PI-1, upstream rlrA, rrgA, rrgB and srtC-1 as 
previously published [56]. In addition, the data obtained further confirm the absence 
of a mRNA coding for the protein annotated as hypothetical protein SP0465 [38]. 
The ratios of H/L obtained for the PI-1 genes with the microarray transcriptome 
analysis were further confirmed by qRT-PCR. The relative quantitation method 
(threshold cycle CT) was used to evaluate the quantitative variation in gene 
expression between the high and low pilus expressing subpopulations for the 5 
different strains tested, relative to each gene examined. The S16 and GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) amplicons were used as the 
endogenous control for the normalization of the data. (Figure 1.11) 
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Figure 1.11. Relative increase of mRNA levels of all the pilus islet 1 components in the H 
sup-population with respect to those in the L sub-population for the TIGR4 strain. The values 
obtained were normalized for the expression levels of GAPDH and S16 for both the 
populations. Error bars indicate the standard deviation obtained combining three indipendent 
experiments. Similar results were obtained for the other 4 S. pneumoniae strains tested 
(OREP4, 19F Tw 14, 6B Fin 12, 35B SME15) (Data not shown). 
 
 
The microarray data analysis comparing the expression profiles of H vs. the L pilus  
expressing sub-populations was then extended to all the genes conserved among 
the isolates, with the aim to identify genes possibly involved in the regulation of pilus 
expression. Interestingly, no other conserved genes, apart from PI-1 components, 
were differentially regulated in all the five strains tested (Figure 1.12A, 1.12B). 
Furthermore, the expression rate of the previously published negative regulators 
(MgrA, HK343, MerR, CbpS, TCS08, mntE, PsaR) [67,69-71] remained unchanged in 
the two sub-populations for all the strains tested (Figure 1.12C).  
A possible reason that could explain why these genes were not up-regulated in the L 
sub-population has to be found in the experimental procedures used to determine the 
involvement in pilus expression regulation. In fact, the putative negative regulators 
have been identified generating and testing the Knock-out (KO) mutants of each 
gene with the assumption that under a particular set of conditions all cells were 
expressing genes in an approximately uniform manner. However, given the biphasic 
expression of the pilus, the colony selection of the KO mutants could also result in 
the fortuitous selection of colonies expressing the pilus at high or at a low level.  
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Figure 1.12. Microarray expression profile analysis of the high versus the low pilus 
expressing sub-populations. A) Hierarchical clustering representation of complete 
microarray data. Blue bars indicate genes significantly differentially regulated in at least one 
strain. B) Gene expression profiling of the genes differentially regulated in A. Numbers 
represent the log2 ratios. * P<0.05. C) Pilus-1 expression repressors reported in the literature 
are not differentially expressed. Gene expression profiling of high versus low pilus 
expressing sub-populations for strains TIGR4 (Clade I), 19F Taiwan 14 (Clade I), OREP4 
(Clade I), 6B Finland 14 (Clade II) and 35B SME 15 (Clade III), by spotted DNA microarray 
analysis. The data are measures of relative gene expression in in vitro growth liquid cultures. 
Red and Green represent high and low experimental high/low pilus expression ratios for the 
5 strains tested, respectively (see scale bar). The columns represent arrays of different 
strains (two hybridizations were performed with independently prepared samples), and the 
rows represent the genes. Red and Green correspond to high and low experimental high/low 
pilus expression ratios for the 5 strains tested, respectively (see log2 ratio scale bar). 
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Expression of the RlrA regulator in Pil- bacteria is sufficient to induce pilus 
polymerization 
In order to better evaluate the regulation of the pilus locus and to check if the positive 
regulator RlrA is sufficient to induce the pilus polymerization, the effects induced by 
the expression of the pilus-1 components under the control of a constitutive promoter 
within Pil- bacteria, were evaluated. In detail, the pMU1328 plasmid, for which was 
already demonstrated the ability to epigenetically replicate in S. pneumoniae [95], 
was used to express in the L population of the TIGR4 strain the positive regulator 
RrlA, the backbone of the pilus RrgB and one of the sortases SrtC-2, required for the 
pilus assembly. The three genes, amplified from the genome were fused by overlap 
extention PCR to the erythromycin constitutive promoter (Pc), and than cloned into 
the pMU1328 plasmid (Figure 1.13). The TIGR4 L sub-population was transformed 
with a pMU1328 plasmid containing the rrgB, the rlrA or the srt-C2 gene (pMU1328 
empty vector was used as negative control). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. (A) Schematic representation of the “empty” plasmid pMU1328 and (B) the 
three constructs cloned in the pMU1328 and used to constitutively express RrgB, RlrA and 
Srt-C2 in the TIGR4 L population.  
 
 
Following transformation, bacteria were studied by FACS analysis (data not shown), 
western blot (Figure 1.14) and immunofluorescence (Figure 1.15). WB analysis 
performed using polyclonal mouse antisera against RrgB and SrtC-2 on whole 
bacterial lysates showed that SrtC-2 is expressed in the TIGR4L sub-population 
when TIGR4L is transformed with pMU1328 Pc_srtC-2 and its expression does not 
influence RrgB expression. Moreover the over-expression of SrtC-2 in TIGR4 PI-1 
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mutant lacking the three sortases and so expressing RrgB in a monomeric form 
(TIGR4∆srtC-1-3) restores RrgB polymerization. (Figure 1.14) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14. SrtC-2 is expressed and functional in bacteria transformed with pMU1328-
Pc-srtC-2. WB analysis performed using polyclonal mouse antisera against RrgB and SrtC-2 
on whole bacterial lysates shows that: SrtC-2 is expressed in the TIGR4L sub-population 
when TIGR4L is transformed with pMU1328 Pc_srtC-2; SrtC-2 expression does not influence 
RrgB expression; and the over-expression of SrtC-2 in TIGR4srtC-1-3 expressing RrgB in a 
monomeric form, restores RrgB polymerization. Samples were loaded as follows: TIGR4 wt 
(lane 1), TIGR4∆srtC-1-3 (lane 2) and TIGR4∆srtC-1-3 transformed with pMU1328-Pc-srtC-2 
(lane 3), TIGR4L transformed with pMU1328 empty vector (lane 4), pMU1328-Pc-srtC-2 
(lane 5), pMU1328-Pc-rlrA (lane 6), or pMU1328-Pc-rrgB (lane 7). 
 
 
In the same way, the performed immune-fluorescence analysis showed that the ratio 
of bacteria expressing the pilus was not altered upon transformation with the 
pMU1328 empty plasmid (Figure 1.15 panels A-C), while the expression of RlrA 
induced polymerization of the pilus in 100% of the S. pneumoniae population (Figure 
1.15 panels D-F). Interestingly, following the expression of RrgB or SrtC-2 (Figure 
1.15 panels G-I and J-L, respectively) the proportion of bacteria able to polymerize 
the pilus on their surface did not change when compared to the control. In detail, 
when RrgB was over-expressed, RrgB was localized in clusters on the Pil- bacterial 
surface (Fig. 1.15 panels G-I), but remained un-polymerized (Fig. 1.14) due to the 
lack of expression of the pilus specific sortases. On the other hand, the expression of 
a functional SrtC-2, which in the presence of the RrgB monomer is sufficient to 
induce RrgB polymerization (Fig. 1.15 panels J-L and Fig. 1.14), did not induce in the 
T4L sub-population any change in pilus components expression or pilus 
polymerization. 
Taken together, these data indicate that the expression of RlrA, unlike that of RrgB 
and SrtC-2, was sufficient to induce the expression of all the other PI-1 components. 
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Figure 1.14. RlrA expression in pilus negative (Pil-) bacteria induces pilus 
polymerization. TIGR4 low pilus expressing bacteria (T4L) transformed with pMU1328 
(panels A-C), pMU1328-Pc-rlrA (panels D-F), with pMU1328-Pc-rrgB (panels G-I) or with 
pMU1328-Pc-srtC-2 (panels J-L) were processed for confocal microscopy immuno-
fluorescence analysis by incubating S. pneumoniae with anti-capsular antibodies 
(Omniserum 1:2000 dilution) (green, left panels) and mouse anti-RrgB antibodies (1:2000 
dilution) (red, central panels). Right panels represent the merged signal of the left and central 
panels. Scale bar is 4 µm. 
 
TIGR4 L 
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Materials and Methods 
 
Bacterial strains and growth conditions 
S. pneumoniae strains were routinely grown over night (ON) at 37°C in 5% CO2 on 
Tryptic Soy Agar plates (TSA) (Becton Dickinson) supplemented with 10 mg/L 
colistine, 5 mg/L oxolinic acid, and 5% defibrinated sheep blood. Liquid cultures were 
carried out statically at 37°C under 5% CO2 humidified atmosphere until A600 = 0.25 
in Todd Hewitt Broth supplemented 0.5% (w/w) yeast extract (THYE) unless 
otherwise specified (Becton Dickinson).  
 
Genomic DNA extraction and PI-1 sequencing 
Genomic DNA extractions were performed from 50 mL of bacterial liquid culture by 
using the Wizard Genomic DNA purification kit following the manufacturer’s 
instructions (Promega). To obtain PI-1 sequences, oligonucleotides matching on 
homologous regions inside the islands were designed and used to amplify and 
sequence the PCR products (Table 1.1). Sequences were obtained by use of an ABI 
3730xl DNA Analyzer and assembled with Vector NTI 10. 
 
Table 1.1. Oligonucletides used to amplify and sequence pilus-1 islets of clade I, II and III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amplifications 
PI-1 clade I
Primer forward Primer reverse
1_clade I AACTGAATTGACACAACGTCTT AGCGACAAGCCACTGTATCATATT
2_clade I ACTTTCTAATGAGTTGTTTAGGCG AGCGACAAGCCACTGTATCATATT
3_clade I CTGGTCGATAACTCCTTCAATCTT GTACGACAAAAGTGTGGCTTGTT
4_clade I GAATGCGATATTCAGGACCAACTA ATCTCACTGAGTTAATCCGTTCAC
5_clade I TGTATACAAGTGTGTCATTGCCAG TTGATAAATTCTCTTTGAAAGTG
6_clade I GATGTTCAAACACCTTATCAGAT TAAACATCTGGTAACTTTGCCCATCTC
7_clade I ACTTTTACTCAGAAAGCTTTGATG CATCGGATCTGTAATCGTACCATT
8_clade I ATCCTGGTACGGATGAAGCAACGG CATCTTCACCTGTTCTCACATTTT
9_clade I GCGGTCTTTAGTCTTCAAAAACA ACCTGTTAAGGTTGCTCCATCTTC
10_clade I TTAACAGAAGCTGAAGGAGCTAA TACATCATTAGATTCTGGTACTTC
11_clade I TTAACAGATGCTGGTTTAGCTAA ACGATTATCTTTATCATTAACTTT
12_clade I GCTGGAGAAATTGCTGTCAAGAA CTGTTTTGTTTCTTCTAAGTAATA
13_clade I TTTGAATGGGTGGCAGATAAGGAC CAAGAGAAAAACACAGAGCCATAA
14_clade I TTGCTTAAGTAAGAGAGAAAGGAGC CAGGAGTATAGTGTCCGCTTTCTT
15_clade I GGCAATGTTGACTTTATGAAGGTG TATCAGCATCCCTTTATCTTCAAAC
16_clade I TGAGATTTTCTCGTTTCTCTTAGC AATAGACGATGGGTATTGATCATGT
17_clade I CCGACGAACTTTGATGATTTATTG ACCAACAGACGATGACTGTTAATC
18_clade I AATGACTTTGAGCCTGTCTTGAT TTCTACAATTTCCTGGCCATTATC
19_clade I GCCATTTGGATCAGCTAAAAGTT TTTTTCAACCCACTACAGTTGACA
20_clade I GCCATTTGGATCAGCTAAAAGTT GCCACACAAGATGTTGATGCTTTT
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Amplifications 
PI-1 clade II
Primer forward Primer reverse
1_clade II AACTGAATTGACACAACGTCTT AGCGACAAGCCACTGTATCATATT
2_clade II ACTTTCTAATGAGTTGTTTAGGCG AGCGACAAGCCACTGTATCATATT
3_clade II CTGGTCGATAACTCCTTCAATCTT GTACGACAAAAGTGTGGCTTGTT
4_clade II GAATGCGATATTCAGGACCAACTA ATCTCACTGAGTTAATCCGTTCAC
5_clade II TGTATACAAGTGTGTCATTGCCAG CACTAACCGTCAACTCGATTCC
6_clade II CATATGAACGTGTGATTCCAGAAG GTTCAATTCCTCTGCATCTGAT
7_clade II ACAGCTAAAACTTATAATTATAG AATCGGTACTAGAGTTAAATGG
8_clade II GGAGCAGAGAGCTAAATTAGTT CGACCATTCGTGTCATAGAAT
9_clade II GAGAAAAGGATTCGTGTAACAGGT CATCTTCACCTGTTCTCACATTTT
10_clade II GCGGTCTTTAGTCTTCAAAAACA GTTAATACTTGCCCATTAGGACCA
11_clade II TTTGACAACTAAAGATGGACTTA ATCCATAGCTACATTATTCAAAGT
12_clade II TATGTTGTTAATACAACAATTC CCGACTTTCTCACCAGTCTTGGC
13_clade II GAATACTCCAAAACCAACTAA GCATCCAATTTTTGTTTTGCAGTT
14_clade II CCACGTGTAAAAACATACGGT CAAGAGAAAAACACAGAGCCATAA
15_clade II TTGCTTAAGTAAGAGAGAAAGGAGC CAGGAGTATAGTGTCCGCTTTCTT
16_clade II GGCAATGTTGACTTTATGAAGGTG TATCAGCATCCCTTTATCTTCAAAC
17_clade II TGAGATTTTCTCGTTTCTCTTAGC AATAGACGATGGGTATTGATCATGT
18_clade II CCGACGAACTTTGATGATTTATTG ACCAACAGACGATGACTGTTAATC
19_clade II AATGACTTTGAGCCTGTCTTGAT TTCTACAATTTCCTGGCCATTATC
20_clade II GCCATTTGGATCAGCTAAAAGTT TTTTTCAACCCACTACAGTTGACA
21_clade II GCCATTTGGATCAGCTAAAAGTT GCCACACAAGATGTTGATGCTTTT
Amplifications 
PI-1 clade III
Primer forward Primer reverse
1_clade III AACTGAATTGACACAACGTCTT AGCGACAAGCCACTGTATCATATT
2_clade III ACTTTCTAATGAGTTGTTTAGGCG AGCGACAAGCCACTGTATCATATT
3_clade III CTGGTCGATAACTCCTTCAATCTT GTACGACAAAAGTGTGGCTTGTT
4_clade III GAATGCGATATTCAGGACCAACTA ATCTCACTGAGTTAATCCGTTCAC
5_clade III TGTATACAAGTGTGTCATTGCCAG TTGATAAATTCTCTTTGAAAGTG
6_clade III GATGTTCAAACACCTTATCAGAT TAAACATCTGGTAACTTTGCCCATCTC
7_clade III ACTTTTACTCAGAAAGCTTTGATG CATCGGATCTGTAATCGTACCATT
8_clade III ATCCTGGTACGGATGAAGCAACGG CATCTTCACCTGTTCTCACATTTT
9_clade III GCGGTCTTTAGTCTTCAAAAACA CCTGGATCTACGAAACCTGCTGCA
10_clade III TTAATTATTCTGCCGCTTGTAA TTAGTAATTGTAAGTTCACCG
11_clade III GTATACTGCAACTTTAAATGCTC GCTCATTCTTCACAACGAATTGTG
12_clade III TGGAAAGATGAAAATCCAGAACCAA TGGAATTGACCATCAGTGTTAGAA
13_clade III ATGCAGCACAAGCTGTAGTAGAT CAAGAGAAAAACACAGAGCCATAA
14_clade III TTGCTTAAGTAAGAGAGAAAGGAGC CAGGAGTATAGTGTCCGCTTTCTT
15_clade III GGCAATGTTGACTTTATGAAGGTG TATCAGCATCCCTTTATCTTCAAAC
16_clade III TGAGATTTTCTCGTTTCTCTTAGC AATAGACGATGGGTATTGATCATGT
17_clade III CCGACGAACTTTGATGATTTATTG ACCAACAGACGATGACTGTTAATC
18_clade III AATGACTTTGAGCCTGTCTTGAT TTCTACAATTTCCTGGCCATTATC
19_clade III GCCATTTGGATCAGCTAAAAGTT TTTTTCAACCCACTACAGTTGACA
20_clade III GCCATTTGGATCAGCTAAAAGTT GCCACACAAGATGTTGATGCTTTT
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Animal immunizations 
Animal treatments were done in compliance with the current law, approved by the 
internal Animal Ethics Committee (AEC numbers 200601, 200602, 200607 and 
200911) and authorized by the Italian Ministry of Health. To generate sera against 
the specific proteins, purified recombinant proteins were used to immunize CD1 mice 
(20g, three doses administered intra-peritoneally two weeks apart) or New Zealand 
rabbits of 2.5 kg body weight (100g, three doses subcutaneous immunization two 
weeks apart) (Charles River Laboratory). Two weeks after the third immunization the 
animals were bled to obtain the sera. A rabbit polysaccharide multivalent antiserum 
(OMNIserum) was purchased from Staten Serum institute (Copenhagen). 
 
Flow Cytometry on whole bacteria 
Bacteria recovered from liquid cultures were stained with mouse antisera raised 
against pilus-1 components or surface exposed proteins (final dilution 1:300). After 
labelling with a secondary FITC conjugated antibody (Jackson Laboratories, dilution 
1:100), bacteria were fixed with 2% paraformaldehyde. Bacterial staining was 
analyzed by using a FACS-Calibur cytometer (Becton Dickinson). Sera from mice 
immunized with PBS (Phosphate Buffered saline) plus adjuvant were used as a 
negative control. To test the pilus-1 expression in the presence of antibodies directed 
against RrgB, the bacteria were grown from an A600 of 0.01 to 1.2 in THYE 
supplemented with anti-RrgB rabbit sera at different dilutions (1:20, 1:50, 1:100). The 
growth was also carried out with rabbit anti-BgaA and with sera derived from animals 
immunized with adjuvant only (1:20, 1:50, 1:100), used as negative controls. When 
the desired A600 was reached, bacteria were processed for FACS analysis as 
reported above by using mouse anti-RrgA as primary antibody. 
 
Immuno-fluorescence staining 
Bacteria were harvested form a plate after an ON growth, washed with PBS pH 7.4, 
fixed with 2% (w/v) paraformaldehyde in PBS and then attached to polylysine-coated 
cover slips. After washing five times with PBS the slides were blocked for 15 min with 
PBS 3% BSA (w/v) (Bovine serum albumin) supplemented with 10% normal goat 
serum (Sigma). Primary and secondary antibodies conjugated with fluorochromes 
(Invitrogen) were diluted in PBS containing 1% BSA and incubated with the bacterial 
cells for 30 min at room temperature. Between incubation steps the bacteria were 
washed thoroughly with PBS. To reduce bleaching of the fluorochromes, the slides 
were mounted in Pro Long Gold antifade reagent with DAPI (Invitrogen). Images 
were obtained using a Carl Zeiss LSM 7MP Laser Scanning Microscope. 
 
Depletion of RrgB positive bacteria 
TIGR4 low pilus expressing bacteria were incubated with rabbit anti-RrgB antibodies 
(1:400 dilution) and then with goat anti-rabbit IgG biotin conjugated (Abcam, 1:1000 
dilution) antibodies. Labelled bacteria were then incubated with Sepharose magnetic 
beads coated with streptavidin (Invitrogen) for 1 h at 4°C. Finally, RrgB positive 
bacteria attached to the Sepharose beads were removed by placing the tubes in a 
magnetic separation rack and recovering the bacterial suspension (containing RrgB 
negative bacteria). 
 
SDS-PAGE and Western Blot analysis 
SDS-PAGE analysis was performed on whole bacterial lysates using Nu-PAGETM 4-
12% Bis-Tris or 3-8% Tris-acetate gradient gels (Invitrogen) according to the 
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manufacturer’s instructions. Hi-MarkTM pre-stained HMW protein standard 
(Invitrogen) served as a protein standard. Gels were processed for Western Blot 
analysis by using standard protocols. Mouse and rabbit antibodies raised against 
recombinant His-Tag-proteins were used at 1:3000 and 1:5000 dilutions, 
respectively. Secondary goat anti-mouse and anti-rabbit IgG alkaline phosphatase 
conjugated antibodies (Promega) were used at 1:5000 and the signal developed by 
using Western Blue Stabilized Substrate for Alkaline Phosphatase (Promega).  
 
Colony immuno-blot 
Bacteria were diluted on blood-agar plates to obtain isolated colonies. Before plating 
the bacteria underwent three sonication cycles (three cycles alternating 15 s of 
sonication and 15 s of pause at 4°C and 20 kHz, with a Vibracell sonicator, Sonic, at 
50% of the maximum power), to ensure that the colonies were derived from single 
bacteria. The effectiveness of sonication was checked by inspection of the bacteria 
under the microscope before and after the treatment. Following ON growth, 
nitrocellulose membrane discs (Millipore) were gently placed on the plates, removed 
after 5 min, heat-treated with microwave irradiation (300 W for 2 min) and then 
processed for Western Blot analysis as described above. 
 
RNA extraction 
RNAprotect bacterial reagent (Qiagen) was added to 2 mL liquid bacterial culture 
(2:1) and the mixture vortexed for a few seconds. After 5 min at room temperature 
the bacterial pellet was recovered by centrifugation (5000 g, 10 min), resuspended in 
1 mL prewarmed (100°C) SDS solution (SDS 2%, 16mM EDTA pH 8.00) and 
incubated at 100°C for 2 min, under vigorous shaking. Prewarmed (65°C) acid 
phenol (1 mL) was then added to the samples, that were incubated for 5 min at 65°C 
under shaking, and then extracted twice with 1 mL Phenol/Chloroform/Isoamyl 
alcohol (25:24:1) and once with 1 mL Chloroform/Isoamyl alcohol (24:1). The 
aqueous phase containing the RNA was recovered by sample centrifugation and the 
RNA precipitation was carried out by adding 2.5 volumes of ethanol and 1/10 vol of 
Na Acetate 3M (pH 4.5). After 2 h of incubation at -20°C and centrifugation (16000 g, 
20 min), the RNA pellet was recovered and purified by using RNeasy Mini Kit 
(Qiagen) according to manufacturer’s instructions. Before the final elution, all RNA 
samples were subjected two times to a DNase I treatment (Qiagen). Total RNA 
integrity check was performed on agarose gel. 
 
Microarray design 
Gene expression analysis was performed by using a custom made microarray based 
on dsDNA fragments (200-500 bp), PCR-amplified on TIGR4 genomic DNA. In the 
design were also included amplicons matching on specific genes selected from 
additional five S. pneumoniae strains (R6, G54, 70585, P1031 and Taiwan-19F 14). 
Genes were considered non-specific if they had a corresponding homologous gene 
in TIGR4 with an identity greater than 80% on at least 80% of the gene length. An 
additional stringency criterion was applied for the gene selection from 70585, P1031 
and Taiwan-19F 14 genomes: genes matching with the amplicons already designed 
on TIGR4, R6 and G54, having an identity of 87% on at least 70 bp of length, and 
having lengths shorter than 180 bp, were removed. Furthermore, amplicons 
corresponding to the genes present in two D39 strain plasmids (pDP1 and pSMB1) 
and in the serotype 2 capsule biosynthesis locus (D39), as well as those 
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corresponding to the PI-1 genes specific for Clade II (Finland 6B-12) and Clade III 
(Taiwan 23F-15) were added. 
Amplification primers were designed by Primer3 software (v. 1.0b) [96]. Usually, one 
pair of primers was designed for each gene; in the case of 337 genes in TIGR4 and 
19 genes in R6, multiple primer pairs (ranging from 2 to 7) were designed on the 
same gene. The resulting coverage in TIGR4 is of 2121/2236 (94.6%) predicted open 
reading frames (25 fragments cover 2 or more genes that are contiguous, extremely 
similar or paralogous). For the other S. pneumoniae strains, the primer pairs 
designed on specific genes cover the following number of open reading frames: 144 
(R6), 22 (G54), 126 (70585), 120 (P1031), 114 (19F Taiwan 14), 5 (D39 pDP1 and 
pSMB1) 15 (D39 capsule), 6 (PI-1 Clade II and Clade III). The possible resulting 
coverage was rechecked by sequence homology between the amplicons and the 
predicted genes in the additional S. pneumoniae strains, requiring at least 70 bp of 
alignment with an identity of at least 87%. The resulting coverage, based on NCBI 
annotations is: R6 1879/2043 (92%), G54 1911/2047 (93.4%), 70585 1890/2323 
(81.4%), P1031 1955/2254 (87.8%), 19F Taiwan 14 1917/2205 (86.9%). 
PCR amplifications were performed on the genomic DNAs (prepared as described 
above), purified using QIAquick-96 PCR purification plates (Qiagen), eluted in ddH2O 
before to be checked by gel electrophoresis on a 96-well format and finally diluted 
with DMSO (dimethyl sulfoxide) 50% (vol/vol). All the PCR-amplified fragments were 
spotted in quadruplicate by using a Microgrid II spotter (Arrayit Corporation) on Type-
VII* aluminium-coated mirrored slides (ArrayJet). Two hundred and one spots were 
spotted with a higher number of replicas (varying from 8 to 32). Negative controls, 
such as PCR-processed empty buffer (spots indicated as 'H2O') and spotter-
processed empty buffer (spots indicated as 'empty'), were also included.  
The chip layout was submitted to the EBI ArrayExpress and is available with the identifier A-
MEXP-2001 
 
Probe labeling and microarray hybridization 
For RNA labeling, 1 g total RNA, prepared as described above, was reverse 
transcribed for two hours at 42°C using Super Script II Reverse Trascriptase 
(Invitrogen), random nonamer oligonucleotides (GE Healthcare) and the 
fluorochromes Cyanine3-dCTP or Cyanine5-dCTP (GE Healthcare). Following the 
reverse transcription reaction, labeled cDNA was treated with RNAse (RNAse One, 
Promega and RNAse H, Invitrogen) at 37°C for 30 min and than purified by using the 
Qiaquick PCR purification kit (Qiagen), according to the manufacturer’s instructions. 
The incorporation efficiency of the Cy3 or Cy5 dCTP was measured by NanoDrop 
analysis. Following heat denaturation (2 min at 95°C), equal amounts of Cy5- and 
Cy3-labeled cDNAs were used to hybridize microarray slides (over night incubation at 
42°C) in microarray hybridization buffer (GE Healthcare) and 50% formamide. Slides 
were then washed once for 5 min in SSC solution (150mM NaCl and 15mM Sodium 
Citrate) 0.2% SDS, and twice for 10 min in 0.1x SSC 0.2% SDS. Finally, the slides 
were dipped 5 times in 0.1X SSC, 2 times in water and then dried with nitrogen. 
Images were acquired with PowerScanner (Tecan) at 5 and 10 m resolution and 
analyzed with Genepix 6.1 (Axon laboratories). 
 
Microarray data analysis and RT-PCR 
Data normalization was performed with the application BASE2 [97] by using a lowess 
transformation, as implemented in the R software environment, by the loess function 
after an intra-slide median centering and a low intensity spot correction (if the 
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average spot intensity was less than one standard deviation of the background signal 
the intensity spot was corrected to the same value of one standard deviation of the 
background signal). 
Differential gene expression was assessed by grouping all log2 ratio values 
corresponding to each gene within experimental replicas and spot replicas, and 
comparing them against the zero value by Student’s t-test statistics (one tail). Genes 
having a t-test p-value < 0.05 were usually accepted as differentially expressed. 
Type-I error rate was estimated by q-value method [98]. A log2 ratio threshold filtering 
was also applied, and genes with a log2 ratio > 1 or < -1 were accepted and classified 
as being significantly changed. The threshold was inferred from log2 ratio distribution 
widths (standard deviation between 0.25 and 0.44 and an average of 0.31) observed 
in each sample. 
Hierarchical clustering was applied as implemented by MeV software (v. 4.2) [99] 
using the Euclidean metrics and the average agglomeration method. 
Microarray data were submitted to the EBI ArrayExpress and are available with the 
identifier E-TABM-1154. 
Gene expression changes were validated by quantitative real-time PCR (qRT_PCR) 
analysis. The primers used for qRT-PCR analysis are reported in Table 1.2. The 
qRT-PCR reaction was performed in a Light Cycler 480 II (Roche) by using the Light 
Cycler RNA amplification kit SYBR green I (Roche) according to the manufacturer’s 
instructions. For each gene, duplicate reactions were performed on the RNA samples 
isolated from separate assays. Analyses were performed with Light Cycler® 480 SW 
1.5 (Roche).  
 
 
Table 1.2. Oligonucleotides used in qRT-PCR to validate microarray data 
 
 
 
 
 
 
 
 
 
 
 
Generation of a TIGR4 srtC1-3 deletion mutant  
A TIGR4 ∆srtC1-3 isogenic mutant was generated by allelic exchange. Fragments of 
approximately 500 bp upstream and downstream the target gene were amplified by 
PCR and spliced into a kanamycin resistance cassette by using overlap extension 
PCR; the PCR fragments were then cloned into pGEMt (Promega) and transformed 
in S. pneumoniae. To select the bacteria in which the target genes were replaced 
with the resistance cassette, bacteria were plated on blood-agar plates with 
kanamycin (500 g/ml). The presence of the isogenic mutation was confirmed by 
Gene name Forward primer Reverse primer 
rlrA TTCAATCTTCTGCTCAGTCATC TACTTAGAGCCACATGCCAACA
rrgA AACATAAAACCTGGGACATACAC CGATTCCATATTGGTTATCATCC
rrgB clade I CACTTGCTAATTATGCAACAGCA ATGTCTTGGTCAATGTCAAATCG
rrgB clade II TCAGATGAAATGACAGAAGGTC CTGTCCCATGTCTTAGTTACTG
rrgB clade III TCAGATGAAATGACAGAAGGTC GCATCAGCCCATGTTTTAGTAA
rrgC GAGATGACCTTCCTTGAGAATCA GTATTCTCCAATCAAGGGAACCT
srtC-1 AGGCTGACATTGATGAACGAATG GTCAAATCCGTAAACATCTTAGC
srtC-2 clade I and III TGATCACTGCTCACAGAGGATT AATAACCACAACCAGAATTGCC
srtC-2 clade II GTTGTCACTGCTCATAGAGGATT AATAACCACAACCAGAATTGCC
srtC-3 GGATCAGCTAAAAGTTGGAGAT AACCATTGAGAGGTTGCAACAC
S16 AGCAGTAGGGAATCTTCGGCAAT AAGGGTCTAACACCTAGCACTC
GAPDH CGACTGGGCTACTGACGGTGTAG GCGAGCACGGCGAAGGTCACCA
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PCR and Western blot analysis. To obtain a TIGR4 ∆srtC1-3 complemented mutant, 
pMU1328-Pc-srtC-2 was transformed into TIGR4 ∆srtC1-3 with conventional 
methods. Transformants selection was performed by supplementing media with 
kanamycin (500 g/mL) and erythromycin (1g/mL) and complementation confirmed 
by Western blot analysis. 
 
Expression of RrgB, RlrA and SrtC-2 in TIGR4 low pilus expressing bacteria 
The rlrA, the rrgB and the srtC-2 genes were amplified from chromosomal DNA of 
TIGR4 strain by PCR by using the primers listed in Table 1.3. The PCR products 
were cloned into the complementation plasmid pMU1328 between BamHI and SalI 
restriction sites [95]. Expression of RlrA, RrgB and SrtC-2 was under the control of 
the erythromycin constitutive promoter (Pc), which was amplified with the primers 
listed in Table1.3 and cloned immediately upstream rlrA, rrgB or srtC-2 (EcoRI, 
BamHI). All plasmids were confirmed by sequencing, and then transformed into 
TIGR4 low pilus expressing bacteria by conventional methods. Transformant 
selection was performed by supplementing media with erythromycin (1µg/mL). 
Bacteria containing the pMU1328 Pc_rlrA, Pc_rrgB or Pc_srtC-2 plasmids were 
analyzed by PCR. Expression of pili on the bacterial surface was detected by 
Western blot, FACS and immune-fluorescence analysis of whole cell lysates. 
 
 
Table 1.3. Oligonucleotides used to constructs pMU1328 plasmids expressing RrgB, 
RlrA and SrtC-2. Underlined sequences correspond to the restriction sites used for cloning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The obtained PCR products were then digested with the appropriated restriction 
enzymes and cloned into the plasmid pMU1328, containing an erythromycin 
resistance marker [95]. The ligations mixtures were then transformed into competent 
cells of Escherichia coli DH10B. Selection of erythromycin resistant transformants 
was performed on plates supplemented with erythromycin (100 g/mL) and insertion 
was confirmed by sequencing. The obtained plasmids along with the empty 
pMU1328 plasmid were then transformed in D39 or TIGR4 wt or deletion mutants 
strains by using conventional methods [100]. S. pneumoniae transformants were 
selected on agarose plates supplemented with antibiotics (erythromycin 1g/mL with 
or without kanamycin 500g/mL), analyzed by PCR to confirm the presence of the 
plasmid and further investigated for the expression of the proteins of interest. 
 
Primer name Primer sequence
Pc _for Eco RI GTGCGTGAATTCGAAACAGCAAAGAATGGCGGAAAC
rrgB _for_BamHI GTGCGTGGATCCATGAAATCAATCAACAAATTTTTA
rlrA _for_BamHI GTGCGTGGATCCATGCTAAACAAATACATTGAAAAA
srtC-2_for_BamHI GTGCGTGGATCCATGGACAACAGTAGACGTTCACGA
Pc _rev_BamHI CAGCGTGGATCCGTAATCACTCCTTCTTAATTACAA
rrgB _rev_SalI CAGCGTGTCGACTGGCTCCTTTCTCTCTTACTTAAG
rlrA _rev_SalI CAGCGTGTCGACCTTTTTGTGTGTAGACAGTACGAT
srtC-2 _rev_SalI CAGCGTGTCGACCGTAGTTTAGTCCTTGACATGACG
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Discussion  
 
Following their first identification in other Gram-positive bacteria, pili have been 
detected on the surface of the major human pathogen S. pneumoniae and shown to 
be immunogenic and involved in pathogenicity in in vivo and in vitro studies 
[46,61,68]. Epidemiological reports have defined that PI-1, coding for the proteins 
implicated in pilus-1 biogenesis, is present in approximately 30% of the 
pneumococcal isolates and exists in three genetically related variants [62,65,101].  
The molecular structure of pilus-1 and the mechanism of pilus assembly have been 
investigated, and a number of putative PI-1 genetic regulators have been described 
[3,59,63,67,69-71,102]. However, still very little is known about the regulation of pilus 
expression, the environmental conditions able to modulate it and the complex 
macromolecular machinery that regulates pili biogenesis. In addition, in all the above 
mentioned studies, S. pneumoniae pilus expression has always been evaluated not 
on a single cell basis, but as an average behavior of a large population.  
In this work, by using detection methods able to discriminate single cells, we have 
compared the expression of the pilus to other known surface exposed virulence 
factors in the laboratory reference strain TIGR4. Unlike the other proteins tested, 
pilus-1 components were found to display a biphasic expression pattern. The two 
phenotypically distinct sub-populations, Pil+ and Pil-, are present in variable ratios in 
all the strains tested. The pilus expression ratio is inherited by daughter cells and is 
not influenced neither by bacterial genetic and epidemiological characteristics nor by 
the in vitro growth conditions tested. Furthermore, the majority of the colonies 
isolated on solid medium from the same strain show a similar pilus expression 
pattern, thus indicating that this may be influenced by some genetic traits of the 
strain, still unidentified. However, some colonies generate bacterial populations 
displaying different ratios of Pil+/Pil- bacteria. Since the isolation of the clinical 
isolates from the human host always implies a process of in vitro growth and 
stochastic colony selection, the pilus expression ratios observed may not be 
representative of the expression of pili in vivo. This aspect needs further 
investigation. 
Interestingly, despite numerous attempts using single colony selection, sub-
populations containing 100% of either Pil+ or Pil- bacteria were never obtained. 
Consequently, the analysis of pilus expression (both by microarray and western blot) 
was performed by comparing two sub-populations, H and L, enriched in Pil+ and Pil- 
bacteria, respectively. Microarray expression profiling showed that no other genes, 
with the exception of the PI-1 components, were differentially regulated in the two 
sub-populations across the five strains tested, including the genes previously 
reported to be RlrA repressors. Moreover, as clearly demonstrated in this work, RlrA 
(unlike RrgB) expression was sufficient to induce the polymerization of a functional 
pilus on Pil- pneumococci, switching the pilus biosynthesis from an “off” to an “on” 
condition. The latter observation is in agreement with previous reports which 
demonstrated that RlrA is a positive regulator of PI-1 genes transcription, able to 
activate its own transcription and to establish a positive feedback loop [56]. Taken 
together these data indicate either that other transcriptional changes remained 
undetected by our assay, or that pilus expression is not dependent on regulators 
located outside PI-1, but directly changes in response to still unidentified external 
stimuli or noise able to activate rlrA transcription. Additional data obtained in our lab 
by analyzing pilus expression at the single cell level in knock-out mutants of the 
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known PI-1 repressors, exclude the possibility of their direct involvement in pilus 
regulation (data not shown), and therefore favor the second hypothesis.  
Although the molecular mechanisms triggering such regulation events are still not 
clear, the data presented in this work suggest that S. pneumoniae pilus expression 
could be an example of bistability, as it was recently suggested for Streptococcus 
pyogenes FCT3 encoded pili and the Ebp-type pili in Enterococcus faecalis [79,80]. 
In fact, this term is usually referred to phenotypic variation examples where: 1) two 
stable expression states coexist within a population; 2) noise or different factors 
operate across the entire population driving cells to switch into the alternative 
expression state and determine the overall switching probability; 3) the regulation 
occurs through the presence of feedback loops, either positive or double negative 
[76,77,103]. Moreover, bistability is epigenetic in nature (not caused by a change in 
the DNA sequence). In this regard, our data exclude the possibility of phase variation 
events within PI-1, but genetic modifications present elsewhere in the genome (still 
unexplored) could indirectly influence pilus expression.  
The molecular basis and the biological benefit of this bistability phenomenon are 
currently unknown. Presumably, such switching mechanisms have evolved as a way 
for bacteria to be phenotypically pre-adapted to survive present or pending adverse 
conditions. Most likely, this heterogeneity helps the bacterium to utilize different 
niches within an ecosystem, and even has the potential to increase the overall fitness 
of the species, and prepare a sub-population of S. pneumoniae cells to promptly 
adapt in response to stress or different environmental conditions.  
In conclusion, this study has shown that pilus expression follows a biphasic pattern, 
and is an on-off regulated mechanism occurring at the transcriptional level and 
involving all the PI-1 components, included the PI-1 positive regulator RlrA (there 
could be multiple promoter regions within PI-1 responding to RlrA positive 
regulation). Further studies are necessary to better clarify the molecular mechanisms 
responsible for the biphasic pilus phenotype. This finding suggests that new 
experimental approaches should be devised to assess the contribution of pilus-1 to 
virulence. In addition, the discovery of this byphasic phenotype points toward the 
need to evaluate the expression of the pneumococcal pilus during infection and to 
understand if in vivo conditions will modulate the pilus expression ratio, or if, for still 
unknown reasons, the coexistence of the two heterogeneous sub-populations is 
necessary to exploit the pilus virulence potential. 
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Introduction 
Pneumococcal pilus-1 components, and in particular the RrgB backbone pilus 
subunits, demonstrated significant efficacy in protecting mice from lethal challenge 
[68], and therefore are evaluated as candidates for the inclusion in a new multi-
component protein-based vaccine against S. pneumoniae [31,104].  
RrgB exists in three variants (I, II and III), which have a degree of protein homology 
of 48-60% [62]. The three allelic variants are protective in vivo against homologous 
challenge with Streptococcus pneumoniae strains, but neither cross-protection nor 
cross-reaction was observed between clades [105]. Since a combination of the three 
RrgB variants could broad the efficacy of a pilus-based vaccine, a fusion protein 
(RrgB321) containing the three RrgB variants in a head to tail organization (Figure 
2.1A), was constructed. Harfouche et al. have demonstrated that RrgB321 elicites an 
antibody response against each of the variants and protectes mice against piliated 
pneumococcal strains of the three clades both by active and passive immunization 
(Figure 2.1B), supporting the validity of this candidate as a potential antigen for the 
generation of a multi-component protein-based vaccine against S. pneumoniae [105]. 
The clearance of S. pneumoniae from the host following the immunization with 
capsular polysaccharide is thought to be primarily mediated by antibody-dependent 
phagocytosis and intracellular killing by alveolar macrophages and 
polymorphonuclear neutrophils (PMNs) recruited to the infection site [106,107]. Due 
to this observation an in vitro assay based on the bacterial killing mediated by 
opsonophagocytosis has been developed [108]. 
The assay measures the functional activity of vaccine-induced antibodies and 
resembles the mechanism by which antibodies provided in vivo protection against 
infection by encapsulated pathogens. 
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Figure 2.1 (A) Schematic representation of the RrgB321 construct, the three full length 
variants of RrgB are linked in a head to tail organization. (B) Protective efficacy provided by 
active immunization with RrgB321. BALB/c mice were either immunized with RrgB321 or 
received alum plus saline (ctrl) and than challenge intravenously with pneumococcal strains 
of the three RrgB clades. Values of bacteraemia for each mouse were reported: circles 
represent values of Log CFU/ml for the blood of single animals, horizontal bars represent the 
mean ± SEM for each group, and the dashed line indicates the detection limit (i.e. no CFU 
were detected in samples positioned below dashed line). Values of P ≤ 0.05, ≤ 0.01, and ≤ 
0.001 are indicated by *, **, and ***, respectively [105]. 
 
 
 
In detail, the assay is classically performed by incubating HL-60 used as effector 
cells (a primary pluripotent cell line differentiated to macrophages) with complement 
and a specific antiserum, and determining the number of surviving pneumococci 
when the mixture is plated on agar plates [109] (Figure 2.2). 
Although the ability to correlate in vitro opsonophagocytic activity with a linear 
increase in in vivo protection has not  been demostrated yet, in the recommendations 
of the World Health Organization for pneumococcal conjugate vaccine it has been 
suggested that the opsonophagocytic activity (OPA) could be considered a surrogate 
of the effectiveness of new streptococcal vaccines and should be a necessary 
component of any vaccine development program [110]. Interestingly, RrgB321 is the 
only protein thus far reported able to induce antibodies which mediate a complement-
dependent opsonophagocytic killing (OPK) of strains representing the three RrgB 
variants at levels comparable to those elicited by antisera against the PCV-7 
glycoconjugate vaccine [105]. 
 
 
III II IN CRrgB321A) 
B) 
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Figure 2.2 (A) Schematic representation of antibodies-mediated opsonophagocytosis by 
neutrophils; the bacterial uptake into phagosomes is followed by bacterial killing through 
multiple mechanisms (From www.cat.cc.md.us/.../ opsonization/u1fig26n.html); (B and C) 
Electron microscope photomicrographes of a macrophage phagocyting pathogens.  From 
http://www.squidoo.com/macrophage 
 
 
Since, as shown in chapter 1, the expression of the pilus is biphasic, we further 
investigate if the pilus expression ratio could impair the protection provided by 
Rrg321. With this purpose, the two stably separated subpopulations expressing the 
pilus at high (H) and low (L) level, were tested in the OPK assay to investigate 
whether RrgB321 antibodies are able to kill both H and L S. pneumoniae populations. 
Moreover the ability of RrgB321 to confer protection in vivo against both populations 
was tested in different mouse models of infection.  
 
 
 
Results and Discussion 
Pilus expression is required to obtain RrgB321 antisera-mediated killing in the 
OPK assay. 
In order to assess if the expression ratio of the pilus in a given strain affects the 
levels of bacterial killing obtained in the OPK assay with RrgB321 antisera, the H and 
L (i.e. the High- and the Low-pilus-expressing) populations of the 6B SPEC strain 
(Figure 2.3) (obtained as detailed in Materials and Methods and in [111]) were tested 
under the same experimental conditions.  
While antibodies against RrgB321 were able to kill up to 80% of 6B SPEC H 
population in a concentration-dependent manner (sera were serially diluted from 
1:200 to 1:437400), no detectable killing of 6B SPEC L was observed. 
 
 
A B 
C 
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Figure 2.3 Pilus expression profiles of the H and L populations used to perform the in vivo 
and in vitro experiments in this study. Pilus expression was analyzed by flow cytometry 
(FACS-Calibur). RrgB321 antisera (1:400 dilution), and FITC anti-rabbit IgG (1:100 dilution) 
served as primary and secondary antibodies, respectively. 
 
 
In contrast, Omniserum, which was used as positive control, showed similar killing of 
both 6B SPEC H and L, with about 100% killing at the lowest dilutions tested (sera 
were serially diluted from 1:400 to 1:874800). No bacterial killing was detectable 
when the assays were performed with negative control sera (Figure 2.4). These data 
indicate that the OPK activity observed in vitro with RrgB321 antiserum is strictly 
dependent on the proportion of the pilus-expressing bacteria of the strain tested.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. RrgB321 antibodies are functional in the OPK assay only against 6B SPEC H S. 
pneumoniae. The OPK assay was performed with both the 6B SPEC H and L populations by 
using: RrgB321 antisera (serial dilutions from 1:200 to 1:437400), Omniserum (serial 
dilutions from 1:400 to 1:874800) and a negative control serum (serial dilutions from 1:12 to 
1:26244). The X and Y axes represent the sera dilutions and the percentages of killing, 
determined as detailed in the materials and methods section. 
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During the OPK assay pilus positive bacteria are selectively killed.  
Due to the bistable expression of S. pneumoniae pilus-1, the separation process 
adopted to obtain the H and L populations leads to the isolation of an enriched, but 
not pure populations of pilus expressing bacteria [111]. In addition, in the OPK assay 
carried out with anti RrgB321 antiserum, the 100% killing was never obtained even 
with the H population (see above). Therefore, we sought to determine if during the 
OPK assay bacteria were switching from an “on” to “off” pilus expression state. With 
this purpose, 6B SPEC H bacteria surviving the OPK assay performed in the 
presence of different dilutions of negative control or RrgB321 antisera were analyzed 
by FACS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Pilus positive bacteria are selectively killed by RrgB321 antibodies in the OPK 
assay. (A) Pilus expression was analyzed by FACS using RrgB321 antibodies on bacteria 
surviving the OPK assay performed with different dilutions of negative control or RrgB321 
sera (serial dilutions from 1:200 to 1:437400). (B) Total bacterial counts at different RrgB321 
serum dilutions were acquired from the OPK assay experiments. The pilus positive (Pil+) and 
negative counts (Pil-) for each RrgB serum dilution were estimated normalizing the 
percentages of pilus positive-negative bacteria obtained by FACS to the total counts. The 
assay was repeated in triplicate. One representative experiment is shown. 
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Pilus expression of bacteria incubated with negative control sera (unrelated protein) 
(Figure 2.5A left panel) was similar, at each serum dilution, to that of bacteria non-
incubated and of bacteria incubated with phagocytes and active complement in the 
absence of specific antibodies (not shown). On the other hand, when the OPK assay 
was performed by using RrgB321 antisera, the proportion of S. pneumoniae not 
expressing the pilus (Pil-) increased at rising sera concentrations (Figure 2.5A right 
panel). To estimate the relative number of pilus-positive (Pil+) and pilus-negative (Pil-
) bacteria surviving the OPK assay, the percentages of pilus-expressing bacteria at 
different RrgB321 serum concentrations (evaluated by FACS analysis) were 
normalized to the actual counts of surviving bacteria. At increasing RrgB321 serum 
concentrations a proportional decrease in the total and in the pilus-positive counts 
was observed, while the pilus-negative counts remained constant at all dilutions 
(Figure 2.5B). 
Moreover, in order to demonstrated that the presence of RrgB antisera did not affect 
S. pneumoniae pilus-expression in liquid cultures three S. pneumoniae strains 
(TIGR4, 6B Fin 12, 35B SME 15) were grown in the presence of antibodies directed 
against RrgB (sera raised against an unreleted protein were used as negative 
control), and were allowed to replicate seven cycles. The expression of pilus-1 was 
then verified by FACS analysis revealing that the pilus expression ratio was 
unaffected by the presence of the RrgB antisera (data not shown). These data further 
confirm that the observed increased proportion of pilus non-expressing bacteria in 
those surviving the OPK assay is only due to the specific RrgB321 antisera-mediated 
killing and not to a switch towards the off-state of pilus expression induced by the 
presence of the serum.  
 
 
RrgB321 protects mice against challenge with either H or L S. pneumoniae 
populations by both active and passive immunization. 
Given the results obtained in the OPK assay in vitro, we set out to determine whether 
immunization with RrgB321 could protect mice against PI-1 positive strains 
independently from their pilus expression ratio by using animal models of sepsis and 
pneumonia. 
In the sepsis model, mice immunized intraperitoneally (i.p.) with RrgB321 were 
challenged intravenously (i.v.) with either the H or L populations of three strains 
representative of the RrgB variants (TIGR4, 6B Finland 12, 35B SME 15) (Figure 2.3 
and Table 2.1). The protective efficacy of RrgB321 against the wild-type strains was 
already established [105]. Bacteraemia at 48 hours and survival were analyzed as 
described in the Materials and Methods section.  
As expected, when the i.v. challenge was performed with the H populations of the 
three strains the levels of protection were always significant, in terms of reduction of 
bacteraemia (ranging from about 1.5 to 3 Logs, according to the challenge strain), 
increase of median survival (from 4 to 10 days), and survival rates (from 32 to 70%) 
(Table 2.1 and Figure 2.6, left panels).  
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Table 2.1 RrgB321 protective efficacy by active and passive immunization against the H and 
L populations of three pneumococcal strains 
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Figure 2.6. CD1 mice immunized with RrgB321 are protected when challenged i.v. with 
either the H (left panels) or the L (right panels) pilus-expressing bacterial populations of the 
indicated strains. Challenge doses and detailed statistical analyses are reported in Table 2.1. 
In the bacteraemia panels circles represent values of Log CFU/ml for the blood of single 
animals, horizontal bars represent the mean ± SEM for each group, and the dashed line 
indicates the detection limit (i.e. no CFU were detected in samples positioned below dashed 
line). In the survival panels the triangles represent survival days for single animals, the 
horizontal bars represent the median survival time for each group, and the dashed line 
indicates the endpoint of observation (animals whose survival time is above the dashed line 
were alive at the end of the experiment). Values of P ≤ 0.05, ≤ 0.01, and ≤ 0.001 are 
indicated by *, **, and ***, respectively. Ctrl = control. 
 
 
Interestingly, significant decrease in bacteraemia (from about 1 to 2 Logs) was also 
observed upon challenge with the L populations of all the three S. pneumoniae 
strains, and a significant increase in median survival time was obtained with TIGR4 L 
and 6B Finland 12 L (Table 2.1 and Figure 2.6, right panels). However, a significant 
survival rate was achieved only with TIGR4 L (Table 2.1).  
In the bacteraemic pneumonia model, following i.p. immunization with RrgB321, mice 
were infected intranasally (i.n). to establish lung infection. Upon challenge with either 
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TIGR4 H or TIGR4 L, bactaeremia was significantly lower and median survival 
significantly increased in mice immunized with RrgB321 with respect to the 
corresponding controls, even though a significant survival rate was obtained only in 
mice challenged with TIGR4 H (Table 2.1 and Figure 2.7). 
Noteworthy, no significant difference was observed between the infectivity exerted by 
the H and L populations of each of the three strains, indicating that the pilus 
expression status does not dramatically affect virulence (P values ranging from 
0.3723 to 0.9027, 0.2415 to 0.7209, 0.2286 to 1.0000 in the i.v. model and P = 
0.0838, = 0.1304, = 1.0000 in the i.n. model for bacteraemia, survival course and 
survival rate, respectively) (Table 2.2).  
 
 
Table 2.2 Comparison of virulence of pneumococcal strains with different pilus 
status. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To assess the relevance of antibodies in the mechanism of protection elicited by 
RrgB321, an experiment of passive serum transfer was performed. Groups of mice 
administered with either RrgB321 antisera or control sera were challenged i.v. with 
TIGR4 wild type (w.t.), TIGR4 H, TIGR4 L, or a TIGR4PI-1 isogenic mutant. As 
shown in Figure 2.8 and Table 2.1, RrgB321 antiserum was able to significantly 
protect mice, against each of the PI-1 positive TIGR4 strains; in the vaccinated 
groups as compared with the control group bacteraemia was significantly reduced by 
over 2 Logs, the median survival was significantly increased by over 5 days, and 
survival rates ≥ 50% were achieved. No protection was observed against TIGR4PI-
1, as expected.  
All the TIGR4 strains tested displayed a level of infectivity comparable to that of 
TIGR4 wt (P values ranging from 0.1267 to 0.6355, 0.1239 to 0.8313, and 1.0000 for 
bacteraemia, survival course and survival rate, respectively) (Table 2.2), confirming 
the results obtained with the H and L populations described above. This is consistent 
with a previous report showing that only experiments of competition between the 
wild-type and pilus-defective mutant strain could demonstrate a difference in 
virulence, otherwise inappreciable [46]. 
 
 
 
challenge 
route (a)
P  (b) 
bacteremia
P  (b)         
survival 
course
P  (c)       
survival rate
i.v. 0,3723 0,3081 0,2286
i.v. 0,9027 0,2415 1,0000
i.v. 0,7984 0,7209 1,0000
i.n. 0,0838 0,1304 1,0000
i.v. 0,6355 0,1239 1,0000
i.v. 0,1267 0,8313 1,0000
i.v. 0,3170 0,4916 1,0000
(a) 
i.v. = intravenous; i.n. = intranasal
(b) 
two-tailed Mann-Whitney U-test
(c) 
two-tailed Fisher's exact test
TIGR4 [clade I] L vs.  wild type
TIGR4 [clade I] ΔPI-1 vs.  wild type
strain [RrgB clade]           
TIGR4 [clade I] H vs.  L
6B-Finland12 [clade II] H vs.  L
35B-SME15 [clade III] H vs.  L
TIGR4 [clade I] H vs.  L
TIGR4 [clade I] H vs. wild type
Chapter 2 
  
56 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. BALB/c mice immunized with RrgB321 are protected when challenged i.n. with 
either the H (left panels) or the L (right panels) pilus-expressing bacterial populations of 
TIGR4. Challenge doses and detailed statistical analyses are reported in Table 2.1. Symbols 
are as described in Figure 2.6. 
 
 
The results presented here indicate that RrgB321 is able to induce an immune 
response that is efficacious when almost all pneumococci express pili, but also that it 
is possible to achieve protection, both by active and passive immunization, even 
when a low proportion of the bacteria express the pilus at the time of the 
experimental infection. This latter observation is in agreement with the biphasic 
regulation of the pilus reported [111,112]. In fact, the data presented here reinforce 
the hypothesis that, once in the host, pilus expression could be switched on by 
undefined mechanisms in the context of the host-pathogen interaction. One possible 
hypothesis is that, during infection of RrgB321-immunized mice, the killing of pilus-
positive bacteria induces other pneumococci to activate pilus expression, 
establishing a balance between the on-state of pilus expression and bacterial killing, 
which results in protection. However, to explain the protection obtained against the L 
populations, the contribution of further, antibody-independent, protective mechanisms 
cannot be excluded. To investigate possible changes of pilus expression in vivo, 
bacteria from blood samples taken from i.v.-infected mice 48h post-challenge were 
analyzed by flow cytometry. For the three strains tested (TIGR4, 6B Finland 12 and 
35B SME 15) we observed that the bacteria recovered from the mice challenged with 
the H population showed a slight decrease (~10%) of the pilus expression ratio with 
respect to the input strain. 
Similarly, pilus expression ratio in mice challenged with the L populations slightly 
increased (~about 10%) (data not shown). These data suggest that S. pneumoniae 
pilus expression can be modulated once in the host. However, we did not observe a 
significant difference in the percentage of piliated pneumococci in the immunized 
versus the non-immunized animals, indicating that such a modulation is independent 
from the immune response. Notably, the 10% increase in pilus expression observed 
at 48h in the L subpopulation is not sufficient to explain the significant levels of 
protection observed. One possible hypothesis could be that, for PI-1-positive strains, 
pilus represents a fitness factor, important during the early stages of infection, and 
that the switch towards the on-state of pilus expression happens at time points earlier 
than that analyzed. 
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Figure 2.8. CD1 mice passively immunized with RrgB321 antisera are protected when 
challenged i.v. with wild-type (w.t.) TIGR4, or with TIGR4 High (H) or Low (L) pilus-
expressing populations. Mice challenged with TIGR4PI-1 (TIGR4 isogenic PI-1 knock-out 
mutant) were not protected by anti-RrgB321 antibodies. Immunization control groups were 
treated with control sera. Challenge doses and detailed statistical analyses are reported in 
Table 2.1. Symbols are as described in Figure 2.6. 
 
 
This would also explain why the protective efficacy of RrgB321 against L populations 
was more evident in terms of bacteraemia at 48h, and less marked in terms of 
survival courses and rates. With this respect, further analyses should be needed to 
achieve a better understanding of the kinetics of pilus expression during 
pneumococcal infection. 
 
 
 
 
 
Materials and methods 
 
Bacterial culture  
S. pneumoniae strains were grown at 37°C in 5% CO2 on Tryptic Soy Agar plates 
(TSA, Becton Dickinson) supplemented with colistine 10 mg/L, oxolinic acid 5 mg/L 
and 5% defibrinated sheep blood (vol/vol). Liquid cultures were performed in Tryptic 
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Soy Broth (TSB, Difco) or in Todd Hewitt Broth supplemented with 0.5% (w/w) yeast 
extract (THYE) (Becton Dickinson). The S. pneumoniae High (H) and Low (L) pilus-
expressing populations used in this study were obtained as reported in chapter 1 and 
in De Angelis et al. [111]. 
For the OPK experiments, bacteria grown on the plates over night (o.n.) were 
inoculated in THYE and grown until A600 = 0.25. Bacteria were then harvested by 
centrifugation, resuspended in THYE, 20% glycerol (vol/vol), 10% Fetal Bovine 
Serum (vol/vol), and frozen in aliquots at -80°C. The frozen stock was titrated by 
plating culture aliquots at serial dilutions and counting CFUs. For intranasal (i.n.) 
challenge and intravenous (i.v.) challenge, bacteria were freshly harvested from TSB 
liquid cultures at A600 = 0.2 and A600 = 0.5, respectively, and then brought to the 
working concentration before administration. The challenge input was titrated by 
plating bacterial suspensions immediately after challenge. 
 
 
RrgB321 recombinant protein expression and purification  
Standard recombinant DNA techniques were used to construct plasmids expressing 
the RrgB321 chimera, consisting of the three full length RrgB variants in a head to tail 
organization and separated by a six aminoacid linker (Gly-Ser-Gly-Gly-Gly-Gly). 
Briefly, rrgB open reading frames (nucleotides corresponding to the N-terminal signal 
sequence and C-terminal cell wall sorting signal motif were excluded from the 
cloning) were amplified by PCR from chromosomal DNAs of S. pneumoniae TIGR4 
(rrgB clade I), 6B SPEC (rrgB clade II) and 35 SME 15 (rrgB clade III) by using 
specific primers listed in Table 2.3. The obtained PCR fragments were digested with 
the appropriated restriction enzymes and ligated into the C-terminal 6xHis-tag 
expression vector pET21b+ (Novagen). The resulting plasmids were confirmed by 
DNA sequencing and then transformed into competent E. coli BL21 DE3 star 
(Invitrogen). Protein expression was induced by the addition of IPTG (isopropyl-β-d-
thiogalactopyranoside, Sigma®) 1mM final concentration to a bacterial culture with 
an A600 of 0.4-0.5 (LB medium supplemented with ampicillin 100 μg/mL). The 
proteins were purified by metal chelate affinity chromatography on His-Trap HP 
columns (GE Healthcare). Pooled fractions containing the purified protein were 
dialyzed o.n. against phosphate-buffered saline (PBS) and stored at -80°C until 
further use.  
 
 
Table 2.3 List of the primers used to create the rrgB321 construct in pET21b+. Underlined 
sequences correspond to the restriction enzyme recognition sites used for cloning. 
Sequences in bold italic encode the 6 AA linker (Gly-Ser-Gly-Gly-Gly-Gly) introduced as a 
spacer before and after the central RrgB clade II subunit. 
 
 
 
 
 
 
 
 
 
 
 
Protein Name Oligonucleotides (5'-3')
rrgB clade III 
For GTGCGT GCTAGC GCGGAACAAAAAACTAAGACACTT
Rev CAGCGT GGATCC CGTGATTTTTTTGTTGACTACTTT
rrgB clade II 
For GTGCGT GGATCC GGCAGCGGTGGCGGTGGC  GCTGCAACAGTTTTTGCGGCGGAC
Rev CAGCGT CTCGAG AGTGATTTTTTTGTTGACTACTTTTGT
rrgB clade I 
For GTGCGT CTCGAG GGCAGCGGTGGCGGTGGC  GCTGCAACAGTTTTTGCGGCTGGG
Rev CAGCGT CTCGAG AGTGATTTTTTTGTTGACTACTTT
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Antisera  
To generate sera against the specific proteins, purified recombinant proteins were 
used to immunize New Zealand rabbits (Charles River Laboratory) of around 2.5 kg 
body weight. Rabbits received three doses of 100 µg protein along with Freund’s 
adjuvant, administered subcutaneously on day 0, 21 and 35, and serum was 
obtained on day 49. Omniserum, the rabbit polysaccharide multivalent antiserum, 
was purchased from Statens Serum Institute (Copenhagen). 
 
Generation of TIGR4 PI-1 deletion mutant 
TIGR4PI-1 isogenic mutant was generated by allelic exchange, as briefly described 
below. Fragments of approximately 500 bp upstream and downstream the target 
gene were amplified by PCR (oligo listed in Table 2.4) and spliced to a kanamycin 
antibiotic cassette by using overlap extension PCR; the obtained PCR fragment was 
cloned into pGEMt (Promega) and the obtained plasmid transformed in TIGR4 with 
conventional methods [100]. Bacteria were plated on selective blood-agar plates 
(kanamycin 500 g/mL). The presence of the isogenic mutation was confirmed by 
PCR and the absence of pilus-1 expression confirmed by western blot analysis.  
 
Table 2.4 Primers used to generate the TIGR4∆PI-1 isogenic deletion mutant 
 
 
 
 
 
 
 
 
 
 
 
 
Animal experiments  
Animal studies were done in compliance with the current law, approved by the local 
Animal Ethics Committee and authorized by the Italian Ministry of Health.  
Female, specific pathogen-free 6-week-old BALB/c or 5-week-old CD1 mice (Charles 
River) received three intraperitoneal (i.p.) immunizations, two weeks apart. Each 
dose was composed of 20 g of recombinant protein, along with 400 g of aluminium 
hydroxide as adjuvant, in a final volume of 200 l of saline. Negative controls 
received the same course of saline plus the adjuvant. Seven days after the last 
immunization mice were bled to obtain immune serum to be used in immunoassays 
and passive protection studies. Two weeks after the third immunization, BALB/c mice 
were challenged intranasally (i.n.), while CD1 mice were challenged intravenously 
(i.v.), via the tail vein. For i.n. challenge, mice anesthetized by intraperitoneal 
injection of xylazine and ketamine (0.1 and 0.01 mg/g of body weight, respectively), 
received into the nostrils 50 µl of bacterial suspension. Bacteraemia was evaluated in 
blood samples taken 48 hrs post challenge and plated on blood-agar plates at serial 
dilutions. After 24 hrs of culture, CFUs were counted and the CFUs/mL of blood 
calculated. Bacteraemia was expressed as log10 (Log) of the CFUs/mL value. After 
challenge, the animals were monitored for 10 (i.n. challenge) or 15 (i.v. challenge) 
PI-1_up
For AATTGTCGACTATAATCTCCACAGTGGGATTTAC
Rev GTTGGCCACTTAGGCCATCATGACCAGATGTAAACTTAATAAAGTCCA                        
PI-1_down
For CTAGCCGGCATTTAAATTTGCATCGCAGGGATTCGCTCAGTGATTGCTG
Rev TTTAGCGGCCGCACAAAGAGCCGGAAAAAGGAACAG
Kan 
For GTCATGATGGCCAAAGTGGCCAACATACTGTAGAAAAGAGGAAGGAAAT
Rev CGATGCAAATTTTAATGCCGGCTAGATCTAGGTACTAAAACAATTCATC
Oligonucleotides (5'-3')
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days. Mice were euthanized when they exhibited defined humane endpoints that had 
been pre-established for the study in agreement with Novartis Animal Welfare 
Policies, and the day of sacrifice was recorded. Survival rates were calculated 
according to the following formula: survival rate (%) = [1 – (% dead vaccinated / % 
dead controls)] x 100.  
For the passive protection experiment, each female 8-week-old CD1 mouse received 
i.v. 50 µL of pooled serum from RrgB321-immunized or negative control mice. Six 
hours later mice were challenged i.v., and bacteraemia and survival (10 days) 
monitored as above.  
The challenge strains and doses are reported in Table 2.1.  
 
Statistical analysis 
GraphPad Prism Software (version 5.0) was used for statistical analyses. For the in 
vivo experiments the following tests were applied: Mann-Whitney U test to analyze 
data of bacteraemia and survival course, and Fisher’s exact test for survival rates . 
One-tailed tests were applied for comparison of vaccinated versus control groups, 
while two-tailed tests were used when comparing control groups each other. Values 
of P ≤ 0.05 were considered and referred to as significant. 
 
Opsonophagocytosis Killing (OPK) assay  
Human proleukemiae cells HL-60 (ATCC CCL240) were maintained in enriched 
medium (RPMI 1640+ Glutamax, Invitrogen; 10% Fetal Bovine Serum, Hyclone; 1% 
Penicillin/streptomycin, Gibco), and differentiated into phagocytes using 0.8% N,N-
Dimethylformamide (DMF, Sigma). After five days treatment with DMF, cells were 
ready to be used in OPK assay [113]. Following heat inactivation (30 min 56°C) 
rabbit antisera were 1:3 pre-diluted in Opsonization Buffer (OPB: Hanks’ Balanced 
Salt Solution [HBSS] with Ca2+ e Mg2+ [Invitrogen], supplemented with 0.1% 
gelatine and 10% inactivated FC1 [Hyclone]) and subsequently 3 fold serially diluted 
in a 96-wells plate (BD corning). Frozen bacteria were thawed, washed once in OPB 
(3000 rpm for 5 min), and then incubated with sera (1200 CFU/well) at RT for 30 min. 
Baby rabbit complement (BRC) was added at 12% and differentiated HL-60 cells 
were distributed at 4x105 per well (HL-60:bacteria ratio 400:1). Plates with reaction 
mixtures (final volume 80µl) were incubated at 37°C, 5% CO2 for 1h, onto a shaking 
platform (400 rpm, LabNet Shaker, ORBIT 300). Phagocytosis was stopped resting 
plates on ice for 15 min. Five microliters of the reaction mixture were tilt plated onto 
THYE Agar for colony count, and the remaining mixture was plated onto TSA/blood 
plates for subsequent flow cytometric analysis of pilus-1 expression. The bacteria 
plated to evaluate bacterial survival were let dry, embedded in THYE Agar 
supplemented with Triphenyl Tetrazolium Chloride dye 100 mg/L (TTC, Sigma), and 
incubated overnight at 37°C, 5% CO2. Colony counts were evaluated by using the 
colony counter ProtoCOL (Synbiosis). Results were expressed as percentage of 
killing, meaning the percentage of bacteria that were killed in samples containing 
bacteria + phagocytes + active complement + sera (BPC’+S), compared to bacteria + 
phagocytes + active complement (BPC’): [(BPC’+S)/BPC’] x 100.  
 
Flow Cytometry on whole S. pneumoniae bacterial cells. 
Bacteria surviving the OPK assay, from a frozen glycerol stock, or from frozen blood 
samples obtained from the mice 48h post-challenge were grown o.n. on TSA/blood 
plates, harvested, stained with rabbit primary antibodies (final dilution 1:300), and 
then with FITC-conjugated secondary anti rabbit antibodies (final dilution 1:100) 
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(Jackson Laboratories). Bacteria were then fixed with 2% formaldehyde and staining 
was analyzed with a FACS-Calibur cytometer (Becton Dickinson). For each sample 
10,000 events were recorded and the percentage of pilus-positive bacteria within 
each sample was estimated with the CellQuest software (Becton Dickinson).        
 
 
 
Conclusions 
 
The use of pilus proteins as well as fimbrial components of Gram-negative bacteria 
as potential vaccine candidates has been extensively investigated. However, 
concerns were raised on the utility of these candidates because of their described 
susceptibility to phase and antigenic variation [114-116]. In this work we present data 
indicating that, despite the bistable expression of S. pneumoniae pilus-1, RrgB321 
immunization confers in vivo protection against both H and L pneumococcal 
populations, and that the presence of anti-pilus antibodies does not induce a switch 
towards the pilus non-expressing state. In addition, the different results obtained in 
vitro and in vivo with the L populations indicate that in this case the OPK assay, 
although a valuable method to establish the functionality of antibodies, does not 
directly predict in vivo results. Different aspects, including the in vivo regulation of 
pilus expression, most likely determine the protection level observed with the L 
populations. 
Therefore, immunization with the RrgB321 fusion protein can be effective to protect 
against the disease caused by all PI-1 positive isolates. Our results support the 
inclusion of this fusion protein in a multi-component protein vaccine against S. 
pneumoniae. 
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Molecular architecture of Streptococcus
pneumoniae TIGR4 pili
Markus Hilleringmann1,3, Philippe
Ringler2,3, Shirley A Mu¨ller2, Gabriella De
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Although the pili of Gram-positive bacteria are putative
virulence factors, little is known about their structure.
Here we describe the molecular architecture of pilus-1
of Streptococcus pneumoniae, which is a major cause of
morbidity and mortality worldwide. One major (RrgB) and
two minor components (RrgA and RrgC) assemble into the
pilus. Results from TEM and scanning transmission EM
show that the native pili are approximately 6 nm wide,
flexible filaments that can be over 1 lm long. They are
formed by a single string of RrgB monomers and have a
polarity defined by nose-like protrusions. These protrusions
correlate to the shape of monomeric RrgB–His, which like
RrgA–His and RrgC–His has an elongated, multi-domain
structure. RrgA and RrgC are only present at the opposite
ends of the pilus shaft, compatible with their putative roles
as adhesin and anchor to the cell wall surface, respectively.
Our structural analyses provide the first direct experimen-
tal evidence that the native S. pneumoniae pilus shaft is
composed exclusively of covalently linked monomeric RrgB
subunits oriented head-to-tail.
The EMBO Journal (2009) 28, 3921–3930. doi:10.1038/
emboj.2009.360; Published online 26 November 2009
Subject Categories: microbiology & pathogens; structural
biology
Keywords: Gram-positive bacteria; mass measurement; pilus;
STEM; Streptococcus pneumoniae
Introduction
Various types of filamentous surface appendages, pili, have
been identified in Gram-negative and Gram-positive bacteria
(Wu and Fives-Taylor, 2001). Pili fulfill manifold functions
during bacterial life cycles, such as host cell invasion, biofilm
formation, cell aggregation, DNA transfer and twitching
motility (Proft and Baker, 2009). Their structure has to
withstand both environmental stress and the activities of
the host immune system. The role of pili as adhesive orga-
nelles is crucial to the survival of pathogenic bacteria, which
have to attach to specific host cells for colonisation and to
establish an infection. While many Gram-negative pili have
been studied in detail over the last decades (Fronzes et al,
2008), the majority of Gram-positive pili have been discov-
ered only recently and their study, initiated through pioneer-
ing work by Schneewind and co-workers on Corynebacterium
diphtheriae pili (Ton-That and Schneewind, 2003; Ton-That
et al, 2004), is in its infancy. In contrast to Gram-negative pili,
which are typically formed by non-covalently linked subu-
nits, Gram-positive pili are extended polymers assembled
from covalently cross-linked pilin subunits and tethered
to the cell wall peptidoglycan (reviewed by Ton-That and
Schneewind, 2004; Telford et al, 2006; Mandlik et al, 2008b).
As demonstrated for the major pilin subunit of C. diphtheriae,
the conserved genetic requirements necessary for pilus for-
mation include the pilin motif (WXXXVXVYPKN), the E-box
domain (YXLXETXAPXGY) and the cell wall sorting signal
(LPXTG), followed first by hydrophobic and then by charged
amino acids (Ton-That and Schneewind, 2003, 2004; Ton-
That et al, 2004). Mass spectrometric studies of pilus frag-
ments of Bacillus anthracis have confirmed the existence of
intermolecular amide bonds between the C-terminal threo-
nine of cleaved sorting signals and the conserved lysine
residue (YPKN) within the pilin motif (Budzik et al, 2008).
However, the structure of the backbone pilin Spy0128 of
Streptococcus pyogenes and mass spectrometric analysis of
pilus fractions showed the isopeptide bond to link the threo-
nine of the sorting signal EVPTG with a conserved lysine that
is close to but not within the pilin-like motif (Kang et al,
2007). Sortases catalyse the reaction between the threonine of
the LPXTG motif and the conserved lysine of the next back-
bone-forming protein (Marraffini et al, 2006; Manzano et al,
2008; Neiers et al, 2009), and also anchor pili in the cell wall,
as demonstrated for several bacterial genera (Swaminathan
et al, 2007; Budzik et al, 2008; Mandlik et al, 2008a; Nobbs
et al, 2008; Neiers et al, 2009).
The Gram-positive bacterium Streptococcus pneumoniae,
also known as pneumococcus, is a major human pathogen
(Lode, 2009). The clinical serotype-4 strain S. pneumoniae
TIGR4 (TIGR4) forms long pili (Barocchi et al, 2006;
Hilleringmann et al, 2008) and its virulence depends on
them (Barocchi et al, 2006; Rosch et al, 2008). However,
the second pneumococcal pilus found recently (Bagnoli et al,
2008) has not been detected. The long S. pneumoniae TIGR4
pili are encoded by the rlrA pathogenicity islet that includes a
Rof-A-like transcriptional regulator (RlrA), three sortases
(SrtC-1, SrtC-2 and SrtC-3) and three structural proteins
RrgA (Swiss-Prot Q97SC3), RrgB (Swiss-Prot Q97SC2) and
RrgC (Swiss-Prot Q97SC1), all of which contain an LPXTG
motif (or variants thereof). As pneumococcal RrgB possesses
the conserved motifs necessary for pilus formation (Ton-That
and Schneewind, 2003, 2004; Ton-That et al, 2004), it has
been suspected to form the backbone of the pneumococcal
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TIGR4 pilus, as indeed implied by immunoelectron
microscopy (immuno-EM; Barocchi et al, 2006; LeMieux
et al, 2006; Hilleringmann et al, 2008). This supposition
was recently proved correct by the work of Fa¨lker et al
(2008), which revealed that only RrgB is required for pilus
formation. Roles as ancillary proteins have been suggested
for the two other components, RrgA and RrgC (Barocchi et al,
2006; LeMieux et al, 2006, 2008; Nelson et al, 2007;
Hilleringmann et al, 2008).
Immuno-EM has been used to unravel the location of the
various pilus proteins since the first molecular description of
Gram-positive pili (Ton-That and Schneewind, 2003).
Antibodies targeted to RrgB, the major pilus building block
of pneumococcal TIGR4 pili, were consistently found to bind
along the filaments (Barocchi et al, 2006; LeMieux et al, 2006;
Hilleringmann et al, 2008). Results concerning the location of
the ancillary proteins RrgA and RrgC are less consistent: anti-
RrgA is reported to bind in regularly spaced clusters along the
pili (LeMieux et al, 2006) and close to the cell surface in the
absence of both RrgB and RrgC (LeMieux et al, 2006; Nelson
et al, 2007). Triple labelling has shown RrgA clusters to
decorate pilus assemblies randomly and independent of
RrgC distribution (Nelson et al, 2007; Hilleringmann et al,
2008), whereas a colocalisation of RrgA and RrgC in clusters
has been observed by double-labelling experiments (Fa¨lker
et al, 2008). In addition, surface topographs acquired by
atomic-force microscopy allowed identification of RrgC at
the ends of detached pili (Fa¨lker et al, 2008). Given these,
in part contradictory, data the localisation of the three
proteins in the pilus is still uncertain. In fact, both local
association of RrgA and RrgC to the pilus shaft and their
incorporation within it have been proposed (LeMieux et al,
2006; Nelson et al, 2007; Fa¨lker et al, 2008; Hilleringmann
et al, 2008).
The pilus-specific TIGR4 sortases, SrtC-1, SrtC-2 and SrtC-3
(formerly SrtB, SrtC and SrtD) diverge in sequence from the
housekeeping sortase, SrtA, the latter being dispensable for
pilus assembly and localisation to the cell wall (LeMieux
et al, 2008). Class-C sortases exhibit functional redundancy
concerning pilus assembly and cell wall localisation
(LeMieux et al, 2008; Manzano et al, 2008; Neiers et al,
2009). One study showed SrtC-1 and SrtC-3 to be required for
incorporation of the ancillary subunits (LeMieux et al, 2008),
while another report suggested SrtC-1 and SrtC-2 to differ
only in their ability to incorporate RrgC (Neiers et al, 2009).
Manzano et al (2008) demonstrated that SrtC-1 assembles
RrgB fibres with high efficiency in vitro, whereas SrtC-3 has a
much smaller fibre-assembling capacity and SrtC-2 has none
at all. Negative-stain EM showed that these in vitro fibres
mimic the pneumococcal pilus backbone with its beaded
appearance. The structures of SrtC-1 and SrtC-3 both exhibit
a flexible lid that shields the active site (Manzano et al, 2008).
Based on this information a universal mechanism for pilus
biogenesis was proposed, where class-C sortases with
encapsulated active sites require activation by their specific
substrate for pilus assembly (Manzano et al, 2008). Most
recently, the structure of SrtC-2, showing the lid for
this sortase as well, corroborated this hypothesis (Neiers
et al, 2009).
Although genetically based functional and epidemiological
studies have substantially increased our understanding of
Gram-positive pili (Telford et al, 2006), information on their
native structure is lacking. Crystal structures of single pilus
subunits of Streptococcus agalactiae (GBS) and S. pyogenes
(GAS) have given novel insights into Gram-positive pilus
structure: Krishnan et al (2007) describe the ancillary protein
GBS52 as having a typical adhesin fold with two immunoglo-
bulin-like domains. The first crystal structure of a Gram-
positive pilus backbone protein showed the GAS shaft sub-
unit, Spy0128, as an extended protein comprising two Ig-like
domains and two intramolecular isopeptide bonds (Kang
et al, 2007). These intramolecular bonds are likely to dictate
pilus integrity, and a model based on Spy0128 describes the
pilus fibre as a chain of individual subunits covalently linked
head-to-tail by intermolecular peptide bonds (Kang et al,
2007; Kang and Baker, 2009).
Given the fundamental structural difference between Gram-
positive pili and their Gram-negative counterparts, and the
significance these pili have during the bacterial life cycle, the
elucidation of their native structure is of importance, not only
to increase our understanding of the biology of Gram-positive
bacteria, but also of related human disease. Here we study the
molecular architecture of a Gram-positive pilus. We visualise
native pneumococcal TIGR4 pili using a combination of elec-
tron microscopic techniques and show the pilus as a chain of
RrgB proteins covalently linked head-to-tail, with the ancillary
proteins RrgA and RrgC at its distal and proximal ends,
respectively. Our results provide the first direct electron micro-
scopic evidence for a simple Gram-positive pilus architecture,
and resolve some of the open questions concerning the loca-
tion and function of RrgA and RrgC.
Results
Overall morphology of native pneumococcal TIGR4 pili
As documented earlier, the surface of the S. pneumoniae
TIGR4 bacteria examined was covered by a non-homogenous
distribution of pili (Barocchi et al, 2006). Different pheno-
types of varying complexity have been described for these
long structures (Barocchi et al, 2006; LeMieux et al, 2006;
Hilleringmann et al, 2008). When TIGR4 bacteria were
imaged by negative-stain EM after minimum perturbation
(see section Materials and methods), the pili were seen as
Figure 1 The pili of S. pneumoniae TIGR4 bacteria imaged by
negative-stain TEM. (A) Fine pili protruding from the bacterial
surface (arrowheads). (B) Second example illustrating the variabil-
ity in pilus number. Note that the individual pili (arrowhead)
appear wider close the cell surface (arrow) due to different negative
staining. (C) Third example illustrating the pilus bundles (#) and
tangles (*) that can form. Some individual pili can also be detected
(arrowhead). Pili can be followed back to the bacterial surface.
Negative stain: 2% phosphotungstic acid (PTA). A high-pass filter
was applied to increase pilus visibility. Scale bar: 100 nm.
Streptococcus pneumoniae pili
M Hilleringmann et al
The EMBO Journal VOL 28 | NO 24 | 2009 &2009 European Molecular Biology Organization3922
fine flexible filaments B6 nm in diameter (Figure 1A–C,
arrowheads) that could be at least 1.5 mm long. In some
cases changes in the degree of negative staining caused
them to appear wider close to the bacterial surface
(Figure 1B, arrow). A distinct tendency of the pili to associate
into bundles of various diameters (Figure 1C, #) or, at larger
distances from the bacterium, to intertwine to form tangles
was also detected (Figure 1C, *). Both types of association
were random and probably dependent on the bacterium, the
negative-staining agent and grid handling. The resulting
aggregates correlate well with the phenotypes of varying
complexity detected previously primarily by immuno-EM
(Barocchi et al, 2006; Hilleringmann et al, 2008), a technique
that cannot match the structural resolution obtained by
negative-stain transmission EM (TEM). Our results suggest
that pneumococcal TIGR4 pili are single filaments and
that the aggregates and super-helical assemblies previously
observed are sample preparation artefacts. The degree to
which the bacterial capsule and attached filaments could be
visualised in the present experiments depended on the nega-
tive stain used. Under optimum staining conditions the fine
B6-nm-wide pili could be followed all the way to the cell
boundary (Figure 1C).
The pilus shaft is formed by RrgB and has RrgA and
RrgC at its ends
TIGR4 bacteria were treated with the murein-hydrolysing
enzyme mutanolysin to release their peptidoglycan-anchored
pili into the supernatant. Using a modified procedure of
Hilleringmann et al (2008), the liberated pili were then
isolated in 10 mM Tris–HCl (pH 8), 1 mM EDTA and 1 mM
DTT (see section Materials and methods). Under the trans-
mission electron microscope TIGR4 pili appeared as long,
flexible,B6-nm-wide filaments (Figure 2A), with the general
morphology observed in situ (Figure 1). The structure
revealed in enlarged views (Figure 2A, inset) bears some
similarity to that of RrgB filaments assembled in vitro
(Manzano et al, 2008). Analysis of the same high-molecu-
lar-weight (HMW) fractions by SDS–PAGE and Western blot-
ting documented the presence of all three pilus proteins,
RrgA, RrgB and RrgC (Figure 2B). In agreement with previous
reports (LeMieux et al, 2006, 2008; Fa¨lker et al, 2008;
Hilleringmann et al, 2008) RrgB was found to be the major
constituent and RrgA and RrgC only accounted for a minor
fraction of the total protein present. The HMW fractions
observed for RrgB confirm the covalent association of
Gram-positive pilus subunits previously reported (Telford
et al, 2006).
Immunolabelling was used to localise all three proteins
within the pilus structure. In contrast to previous reports, we
directly visualised primary antibodies to overcome the reso-
lution limit imposed by the size of the primary and secondary
gold-bearing antibody complex (Barocchi et al, 2006;
LeMieux et al, 2006; Fa¨lker et al, 2008; Hilleringmann et al,
2008). The polyclonal antibodies generally used for Western
blots were purified further according to the protocol of
Mueller et al (2005), were highly specific and did not show
cross-reactivity (Supplementary Figure S1). Their concentra-
tions were adjusted to show binding but minimise the
number of free antibodies in the solutions. Anti-RrgB–His
antibodies decorated the pilus shaft at irregular intervals and,
having two binding sites, often linked pili together forming
ladder- and net-like assemblies depending on the degree
of lateral cross-linking (Figure 2C and Supplementary
Figure S2). Views of single antibodies are shown in the
inset of Figure 2D for comparison. In contrast to anti-
RrgB–His antibodies, antibodies against RrgA–His only
bound at the end of pili, generally clustering and, as they
are divalent, frequently linking two pili together in typical
v-shaped assemblies not otherwise observed (Figure 2D and
Supplementary Figure S3). Anti-RrgC–His also bound at the
end of the pilus shaft and sometimes clustered there
(Figure 2E and Supplementary Figure S4). As RrgC is two
times smaller than RrgA (see below and Figure 3), the
capacity of anti-RrgC–His to link two fibres appears to be
much diminished. As polyclonal antibodies were used, the
formation of antibody clusters does not necessarily mean that
there is more than one copy of the labelled protein present.
Neither anti-RrgA–His nor anti-RrgC–His decorated the pilus
shaft, and the ladder-like assemblies typical of anti-RrgB–His
were not formed. Occasionally an antibody was extremely
close to the side of a pilus, but this was a chance occurrence
rather than specific binding as it was rare and reflected
the free antibody concentration and distribution on the
grid. Accordingly, the results show that RrgA and RrgC
are present at the ends of the pilus shaft formed by RrgB,
and strongly imply that these two ancillary proteins are
neither incorporated in nor associated with it. In confirma-
tion, mutant bacteria lacking either RrgA or, RrgC or both
(Supplementary Figure S5) still form long pili with the shaft
morphology of the wild type (see below; Supplementary
Figure S6 and reference Fa¨lker et al, 2008).
All three pilus components have an elongated structure
with several domains
To acquire further structural information, the three pilus
components were expressed in Escherichia coli with an
engineered C-terminal His6 tag but otherwise mimicking the
predicted processed forms, which are lacking the N-terminal
signal sequence and the C-terminal region starting from the
respective LPXTG sorting motif (Supplementary Figure S7).
The affinity purified RrgA–His (93.37 kDa), RrgB–His
(66.29 kDa) and RrgC–His (40.26 kDa) proteins were exam-
ined by EM. First, the oligomeric state of RrgA–His was
defined by scanning TEM (STEM) mass measurements. The
measured mass of 108 (±42)kDa (n¼ 319) clearly showed
the large majority of the protein to be monomeric
(Supplementary Figure S8A). Also, all three proteins were
imaged by negative-stain TEM. The average projections cal-
culated by single-particle analysis of TEM electron micro-
graphs and STEM single-shot images are shown in Figure 3.
RrgA–His is a flexible, B18-nm-long, elongated macromole-
cule with four domains of unequal size. These domains give
the structure a distinct taper, one end beingB5 nm wide and
the other B3 nm wide (Figure 3A). RrgB–His is an B12-nm-
long, elongated particle (Figure 3B). Up to three domains can
be detected and, depending on the orientation, a lateral
protrusion is sometimes discernible. The domains are almost
5 nm wide without and B6.5 nm wide with the protrusion.
Being of about 2/3 the length of RrgA–His and roughly the
same width, the imaged RrgB–His was monomeric. The
overall shape of the RrgB–His particles is compatible with
the partial 2.2-A˚ X-ray structure of Spy0128 (aa 18–308), the
major pilin subunit of the Gram-positive human pathogen
Streptococcus pneumoniae pili
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Figure 2 Constituents of isolated TIGR4 pili and their structural significance. (A) TEM image of TIGR4 pili isolated in Tris buffer and negatively
stained with 2% UAc. A beaded structure is evident in an enlarged view (inset). (B) Western blot analysis of the HMW pilus fractions. RrgB
forms a ladder of HMW polymers (lane 1, anti-RrgB-His antibody). Loading equal volumes showed the HMW pilus material to contain different
amounts of RrgA (lane 2), RrgB (lane 3) and RrgC (lane 4) as measured by Western blotting with anti-RrgA–His, anti-RrgB–His and anti-RrgC–
His antibodies, respectively. (C) TEM images of TIGR4 pili after incubation with antibodies to RrgB–His. Single antibodies link the pili laterally
to form ladder-like structures. (D) TEM image of TIGR4 pili after incubation with antibodies to RrgA–His. A cluster of antibodies (white arrow)
links the pili together at their ends; the individual antibodies are difficult to distinguish. Such v-shaped pilus assemblies were typical. Inset:
various orientations of individual antibodies and traces indicating their outer contours. (E) TEM image of a TIGR4 pilus after incubation with
antibodies to RrgC-His. A single antibody is attached to the end of the pilus (white arrow). Note the absence of antibodies along the pilus shafts
in panels D and E. Scale bars: panel A, 100 nm, inset 20 nm; panels C–E and inset in panel D, 20 nm.
Figure 3 EM of the purified pilus constituents. Representative negative stain (2% UAc) TEM averages (left gallery) and contrast reversed STEM
single-shot, dark-field images (right gallery) are shown. (A) RrgA–His. The averages were calculated by sorting 592 single projections into 19
classes. (B) RrgB–His. The averages were calculated by sorting 706 single projections into 14 classes. (C) RrgC–His. The averages were
calculated by sorting 256 single projections into 12 classes. Scale bar: 10 nm.
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S. pyogenes (Kang et al, 2007). With 291 residues this construct
is much smaller than RrgB, which comprises 608 residues in
its predicted processed form. This explains the different
dimensions of the two structures, the Spy0128 construct
being 2–3 nm wide and 9.8 nm long, that is, half as wide
and 20% shorter than the RrgB–His class averages. Images of
RrgC–His, the smallest of the three pilus proteins, revealed up
to 4-nm-wide and 10-nm-long elongated particles with 2–3
domains (Figure 3C). From these dimensions the protein was
also monomeric, as confirmed by size-exclusion chromato-
graphy (data not shown).
The shaft subunits are RrgB monomers and these give
the pilus a distinct polarity
The mass-per-length of freeze-dried, unstained, isolated
TIGR4 wt pili (Figure 4A) was measured by STEM to deter-
mine the stoichiometry of their RrgB subunits. The 395
segments evaluated gave a histogram with a single peak at
6.4 (±1.4)kDa/nm (standard error, 0.07 kDa/nm; Figure 4B).
Given the ±5% overall precision of the STEM measurement
(Mu¨ller and Engel, 2006), this indicates the presence of one
65.44-kDa RrgB monomer every 10.2 (±0.5)nm on average,
which is slightly shorter than the length determined for
a recombinant RrgB-His monomer, B12 nm. As expected
the mass-per-length of TIGR4 DrrgA pili was comparable
(Supplementary Figure S8B).
The high signal-to-noise ratio of the STEM was also
exploited to examine negatively stained TIGR4 pili. These
images confirmed that the pilus is formed by a single string of
subunits and revealed a well-defined protrusion extending
at irregular intervals from the filament shaft like a ‘nose’
(Figure 4C and D). Most importantly, they showed that this
‘nose’ points in a defined direction giving the pilus a distinct
polarity. Where the boundaries of single subunits could be
discerned (Figure 4C and Supplementary Figure S9, lines),
their shapes correlated well to those of the RrgB–His class
averages and single projections implying that the pilus ‘nose’
is the protrusion observed in some orientations of the macro-
molecule. In agreement with the measured mass-per-length,
the subunit spacing (10.2 (±0.6)nm; marked by lines in
Figure 4C and Supplementary Figure S9) was somewhat
less than the length of an RrgB–His monomer, implying that
adjacent RrgB monomers may overlap slightly, as detailed in
Figure 4E and F. Close examination of the pili formed by
TIGR4 DrrgC, TIGR4 DrrgAC bacteria revealed the same sub-
structure, that is, a single string of monomeric RrgB subunits,
with ‘noses’ protruding at irregular intervals (Supplementary
Figure S6, insets).
As the ‘nose’ was not always visible at regular intervals along
the pilus shaft under the preparation conditions used, the RrgB
monomers do not appear to assemble according to a defined
helical rule. In any case, the covalent bonds formed between the
monomeric RrgB subunits and further possible molecular inter-
actions not only allow the filaments to bend freely, but also
permit a degree of rotation around the long filament axis under
the forces encountered on adsorption to the EM grid.
The ancillary proteins RrgA and RrgC are localised
at opposite ends of the pilus shaft
Knowledge of its existence allowed the fine ‘nose’ feature to
be detected on TEM images and showed it to consistently
point in one direction for longer pilus stretches, indicating
that the individual RrgB pilus subunits are linked head-to-tail.
Examination of the immunolabelling images with this infor-
mation also clearly showed that anti-RrgA–His and anti-
RrgC–His labelled opposite ends of the pilus shaft (Figure 5
and Supplementary Figure S10). The role of RrgA as a pilus-
associated adhesin that is expected to locate at the distal end
(Nelson et al, 2007; Hilleringmann et al, 2008), would suggest
that RrgC is located at the proximal end of the pilus shaft.
In accordance, the pili formed by a TIGR4 DrrgC genetic
background (TIGR4 DrrgC and TIGR4 DrrgAC) detached
more easily from the bacteria, resulting in the appearance
of more HMW pili material in the culture supernatant
(Supplementary Figure S11).
Discussion
Since Ton-That et al’s description of the pili of C. diphtheriae
(Ton-That and Schneewind, 2003), many Gram-positive bac-
teria have been shown to possess such filamentous appen-
dages, including group-A Streptococci (Mora et al, 2005),
group-B Streptococci (Lauer et al, 2005), S. pneumoniae
(Barocchi et al, 2006), Enterococcus faecalis (Nallapareddy
et al, 2006), Bacillus cereus (Budzik et al, 2007) and actino-
myces (Wu and Fives-Taylor, 2001; Ton-That et al, 2004).
In addition, probable pilus loci have been identified by genome
sequencing of Streptococcus spp. (Osaki et al, 2002; Xu et al,
2007). The adhesive function of pili (Barocchi et al, 2006;
Dramsi et al, 2006) is critical for the attachment of pathogens
to specific host cells during colonisation, and explains why
pilus expression increases the pathogenicity of various Gram-
positive bacteria in animal models (Hava and Camilli, 2002;
Abbot et al, 2007; Maisey et al, 2007; Rosch et al, 2008). This
central function has promoted several EM analyses of native
pili attached to bacterial cells and after purification (LeMieux
et al, 2006; Nelson et al, 2007; Fa¨lker et al, 2008;
Hilleringmann et al, 2008), as well as X-ray studies of
Gram-positive pilus components (Kang et al, 2007;
Krishnan et al, 2007) and of the pilus assembly machinery
(Manzano et al, 2008; Neiers et al, 2009).
We have used TEM, antibody labelling and STEM to
elucidate the structure of the native TIGR4 pilus. The shaft
is anB6-nm-wide, single chain of slightly overlapping, head-
to-tail covalently linked, monomeric RrgB subunits and can
be at least 1.5 mm long. According to the mass-per-length
measurements by STEM, a 1.5-mm-long pilus comprises
approximately 150 RrgB monomers. TIGR4 pili assembled
in a DrrgA, DrrgC or DrrgAC genetic background were also
examined after purification and exhibit the same length and
morphology as the wt pilus. The two ancillary proteins RrgA
and RrgC are found at opposite ends of the shaft. RrgA is
distal and consequently, RrgC proximal to the bacterium, as
illustrated in Figure 6.
The proposed model agrees with functional implications
derived from the structures of the S. pneumoniae sortases
SrtC-1 and SrtC-3 (Manzano et al, 2008), and SrtC-2 (Neiers
et al, 2009). All of them possess an encapsulated active site
that is postulated to be activated by the specific LPXTG-like
motifs found in RrgA, RrgB and RrgC. These motifs are
known to have profound consequences for catalysis
(LeMieux et al, 2008), and could be indicative of a controlled
sequential pilus assembly process. Although the sequence of
this process remains to be unveiled, it would ensure RrgA to
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be at the distal tip of the pilus shaft assembled from RrgB,
which is the only one of the three pilins to have both the
pilin and the LPXTG domain (Supplementary Figure S7B).
Incorporation of the RrgC protein at the proximal end
would then terminate the pilus assembly process and
induce cell wall linkage similar to that observed for SpaB
in C. diphtheriae (Mandlik et al, 2008a) or GBS150 in
S. agalactiae (Nobbs et al, 2008).
In spite of this agreement our model is in contrast to other
reports, which state that ancillary proteins RrgA and RrgC are
Figure 4 STEM analysis of isolated TIGR4 pili. (A) STEM dark-field image of unstained, freeze-dried TIGR4 pili; the regions selected for mass-
per-length measurement are indicated. (B) The mass-per-length histogram obtained from this sample. The peak at 6.4 (±1.4)kDa/nm
(n¼ 395) shows the pilus filament to be a single string of RrgB monomers and predicts the presence of one monomer every 10.2 (±0.5)nm.
(C, D) Contrast-reversed STEM dark-field images recorded at a magnification of  106 from negatively stained TIGR4 (2% PTA). A nose-like
protrusion is present at irregular intervals and gives the filaments a defined polarity. Indeed, individual pilus subunits can be distinguished and
have the same shape as RrgB–His monomers; compare with Figure 3B. Subunit boundaries are indicated by white lines in panel C (analysed in
Supplementary Figure S9) and for panel D by the model in panel E. (E) Highly contoured TEM images of RrgB–His monomers (average length
12.2 (±0.5)nm) matched, without straightening, to the subunits of pilus (D), illustrating that its RrgB subunits overlap; the RrgB monomers are
shown in alternating shades of grey and their ends are marked by dotted lines to facilitate visualisation. (F) Outline of the outer contours of
panel E superimposed on panel D. Scale bar: panel A, 30 nm and panels C–F, 10 nm.
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either incorporated in or associated with the pilus shaft
(LeMieux et al, 2006; Nelson et al, 2007; Fa¨lker et al, 2008;
Hilleringmann et al, 2008). Immuno-EM showed RrgC and
RrgA to be in clusters along the length of the pilus shaft
(LeMieux et al, 2006; Hilleringmann et al, 2008), sometimes
together as indicated by double-labelling studies (Fa¨lker et al,
2008). The discrepancy to the observations presented here is
explained by the lower resolution of the previous immuno-
EM studies, which could not resolve single pili with certainty,
but rather visualised immunogold-labelled pilus bundles.
LeMieux et al (2008) came to a similar conclusion speculating
that the observed clustering of RrgA simply manifests the
bundling of different-length pili with RrgA at their tips.
Immunogold labelling cannot prove this hypothesis because
single pili within a bundle cannot be resolved. Negative-stain
EM can achieve higher resolution. Using this technique we
first demonstrate that pili emerge from the cell surface as
single, B6-nm-wide filaments, which then form bundles or
tangle at random (Figure 1). Second, by isolation of native
pili using a modified protocol we obtain a higher-resolution
definition of the pilus shaft by STEM dark-field imaging
of single pili, and show their previously observed beaded
structure (Manzano et al, 2008) to arise from single RrgB
monomers linked head-to-tail with a periodicity of about
10 nm (Figure 4C–F and Supplementary Figure S9). This
periodicity is compatible with STEM mass-per-length mea-
surements; 6.4±1.4 kDa/nm (Figure 4B) also translates to
about 1 RrgB monomer/10 nm. Third, the well-defined pro-
trusions on the filaments, the ‘noses’, result in clear polarity
and indicate a head-to-tail subunit assembly (Figure 4C–F).
Figure 5 Localisation of the ancillary proteins, RrgA and RrgC.
TEM of negatively stained (2% UAc) immunolabelled TIGR4 pili,
enlarged to show pilus polarity. (A) Pili labelled with anti-RrgA-His;
the noses point away from the antibody cluster. The antibody
cluster is indicated by a white arrow. (B) Pilus labelled with anti-
RrgC–His; the noses point towards the antibody. The antibody is
indicated by a white arrow. As RrgC anchors the pilus to the cell
wall, as suggested by the release of pili in the absence of RrgC
(Supplementary Figure S11), the black arrows in panels A and B
point away from the bacterium. Scale bar: panels A and B, 20 nm.
Figure 6 Model of S. pneumoniae pilus. (A) The TIGR4 pilus
consists of a shaft composed of RrgB, with RrgA at its distal and
RrgC at its proximal end. Sortase SrtC-1 mediates the polymerisa-
tion of RrgB (red) via the LPXTG motif (*, IPQTG) and pilin motif
(#) (Manzano et al, 2008) into a single string of monomers,
covalently linked head-to-tail. The nose-like feature of RrgB gives
the pilus a clear polarity. C-type sortases also control the addition of
the ancillary proteins RrgA and RrgC, and anchor RrgC to the
peptidoglycan cell wall, depending on the recognition of the re-
spective LPXTG motifs YPRTG (RrgA) and VPDTG (RrgC; LeMieux
et al, 2008; Neiers et al, 2009). RrgA is located at the distal end of
the pilus, while RrgC is proximal to the bacterium. This is in
agreement with the proposed role of RrgA as adhesin (Nelson
et al, 2007; Hilleringmann et al, 2008) and the release of pili into
the supernatant when RrgC is not present. RrgA and RrgC do not
localise together in these single pili and are neither incorporated
into the pilus shaft nor present along its length as proposed earlier
(LeMieux et al, 2006; Fa¨lker et al, 2008; Hilleringmann et al, 2008).
(B) The ability of RrgA and RrgC to form a heterodimer (LeMieux
et al, 2008) suggests a site in RrgC that can be covalently linked to
an LPXTG motif from either RrgA or RrgB. The inability of RrgA
and/or RrgC to form polymers may indicate that (i) RrgA has no site
to interact with an LPXTG motif and (ii) RrgC has an LPXTG motif
that activates only the C-type sortase, which links it to the cell wall.
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These ‘noses’ relate to lateral protrusions on images of
negatively stained, recombinantly expressed RrgB–His mono-
mers (Figure 3B). In agreement, antibody labelling demon-
strated the pilus shaft to be exclusively comprised of RrgB
proteins (Figure 2C–E and Supplementary Figure S2–4).
Fourth, once these basic simple features of the TIGR4 pilus
had been defined by high-resolution STEM, we could also
recognise them on close inspection of TEM images recorded
at lower magnification. Based on the polarity imposed by the
‘noses’ and primary antibody labelling it can be said that
RrgA and RrgC are located at opposite ends of the pilus shaft
(Figure 5 and Supplementary Figure S10). In contrast to
immuno-EM, where a secondary, gold-labelled antibody is
necessary, direct visualisation of the primary antibody pro-
vides the resolution required to locate a specific protein
associated with a single pilus shaft. With the new higher
resolution data obtained, the previously reported clusters of
surface-located RrgA can be interpreted as the distal ends of
several interacting individual pili that may emerge from
different sites of the cell wall or have different length.
The location of RrgA is assigned as distal as this protein
has recently been described as an adhesin (Nelson et al, 2007;
Hilleringmann et al, 2008). This implies that RrgC is at the
proximal end of the pilus, which must be anchored in the
bacterial cell wall. In C. diphtheriae the protein SpaB is
proposed to act as the terminal subunit and cell wall anchor
in pilus assembly, and in its absence the pili formed
are largely found in the medium (Mandlik et al, 2008a).
In S. agalactiae the pilus is covalently linked to the cell
wall via the ancillary pilus subunit GBS150, and its absence
provokes the release of pili into the culture supernatant
(Nobbs et al, 2008). Similarly, less HMW pneumococcal
TIGR4 pili are found in the supernatant of wt S. pneumoniae
liquid cultures than in the supernatants of DrrgC and DrrgAC
mutants, the apparent enhanced pilus loss of the latter
over the DrrgC mutant probably resulting from the missing
adhesive function of RrgA (Supplementary Figure S11).
Accordingly, RrgC is likely to be the terminal pilus subunit
and to warrant cell wall anchoring. The proposed pilus model
(Figure 6) agrees with the fact that RrgB assembles in vitro in
the presence of the pilus-polymerising transpeptidase SrtC-1
(Manzano et al, 2008) and in vivo in the absence of both RrgA
and RrgC (Supplementary Figure S6C and Fa¨lker et al, 2008;
LeMieux et al, 2008). The observation that the accessory
subunits RrgA and RrgC are found in similar quantities within
each ‘rung’ of the ladder of bands arising from pili of different
lengths on Western blots corroborates this model as well
(LeMieux et al, 2008). Our results confirm the observation
that RrgA and RrgC can form covalent heterodimers, but not
higher order polymers in the DrrgB background. As indicated
in our model, this implies that the IPQTG motif in the RrgB
protein can be covalently linked to a critical lysine in RrgC,
and that in the absence of RrgB the same site in RrgC is linked
to the YPRTG motif of RrgA. Whereas RrgC must have
another site to be anchored to the cell wall, RrgA appears
to expose a single motif for sortase action (Figure 6 and
Supplementary Figure S7).
Our model of the pilus shaft (Figure 6) extends the
previous model of the S. pyogenes pilus created on the
basis of the 2.2-A˚ Spy0128 structure and mass spectrometry
(Kang et al, 2007). No overlap of subunits is proposed in the
Spy0128 filament model. In contrast, we predict an overlap of
about 1 nm for RrgB, in accordance with the sequence-based
pneumococcal pilus assembly model (Telford et al, 2006).
The overlap is based on pilus images recorded at  106
magnification, the mass-per-length values provided by
STEM and the dimensions of RrgB–His monomers. A major
difference in the mass of Spy0128 (aa 18–308; Kang et al,
2007) and the integrated RrgB monomer (608 aa) may explain
this overlap, but a high-resolution structure of full-length
RrgB is required to prove our hypothesis.
Using quantitative EM techniques we have visualised the
molecular details of a Gram-positive pilus for the first time.
Together with the sequence analysis presented by Manzano
et al (2008), our observations suggest a pilus architecture that
is likely to be valid for other Gram-positive pili. It implies a
simple pilus assembly mechanism, and indicates novel sites
for therapeutic intervention.
Materials and methods
Bacterial strains and culture conditions
S. pneumoniae type-4 strain TIGR4 was used (Tettelin et al, 2001).
The TIGR4 DrrgA mutant used initially was kindly donated by B
Henriques-Normark (Karolinska Institutet, Stockholm). Later
TIGR4 DrrgA, TIGR4 DrrgB, TIGR4 DrrgC and TIGR4 DrrgAC
mutants were created by PCR-based overlap extension (Supple-
mentary data and Supplementary Tables S1–S2). The pneumococcal
strains were stored at801C in 12% glycerol and routinely grown at
371C under 5% CO2 on Tryptic Soy Agar (Becton Dickinson)
supplemented with 5% defibrinated sheep blood or in Todd–Hewitt
Yeast Extract (THYE) broth. When appropriate, erythromycin and
kanamycin (Sigma-Aldrich) were used as selection markers.
Expression and purification of RrgA, RrgB and RrgC
Recombinant expression and purification of His6-tagged pilus
proteins was performed as described previously (Hilleringmann
et al, 2008). When necessary a size-exclusion chromatography step
was performed after affinity purification. Purified proteins were
finally dialysed against 10 mM Tris–HCl (pH 8), 1 mM EDTA and
0.5 mM DTT.
TIGR4 pilus purification
The native pili of TIGR4 wt and TIGR4 DrrgA, TIGR4 DrrgC and
TIGR4 DrrgAC were purified essentially according a protocol
described by Hilleringmann et al (2008) treating bacteria with
mutanolysin, a murein-hydrolysing enzyme (Sigma M9901), to
liberate covalently peptidoglycan-anchored pili into the super-
natant, but using a Tris buffer (10 mM Tris–HCl (pH 8), 1 mM EDTA,
1 mM DTT)-based procedure. In addition the following modifica-
tions were applied: harvested bacteria were washed in Tris buffer
and resuspended in Tris containing protoplast buffer (Tris buffer,
20% sucrose). Final sample dialysis against Tris buffer was
performed using a molecular weight cut-off of 300 kDa (Spectra/
Por Biotech cellulose ester).
SDS–PAGE and Western blot analysis
SDS–PAGE analysis was performed using NuPAGE 3–8% Tris
Acetate Gels (Invitrogen) according to the instructions of the
manufacturer. HiMark pre-stained, HMW protein standard (Invitro-
gen) served as the protein standard. Western blot analysis was
performed using standard protocols. Unless otherwise stated,
antibodies against recombinant RrgA–His and RrgB–His were used
at 1:10 000 dilution, and against RrgC–His at 1:2000 dilution.
Secondary goat anti-mouse HRP antibodies were diluted 30 000 .
Animal sera and antibodies
Polyclonal mouse antibodies against recombinant RrgA–His, RrgB–
His and RrgC–His were produced in our laboratory. For immuno-
labelling of isolated native pili, antibodies were purified to 100%
specificity against their respective proteins using the protocol
described by Mueller et al (2005).
Streptococcus pneumoniae pili
M Hilleringmann et al
The EMBO Journal VOL 28 | NO 24 | 2009 &2009 European Molecular Biology Organization3928
Immunolabelling of the isolated pili
The respective affinity-purified antibodies were individually in-
cubated with wt or DrrgA TIGR4 pili (control experiments)
overnight or during 50 min at 41C in a series of runs covering a
range of concentrations. Samples were inspected by negative-stain
TEM. The conditions were optimised to yield good labelling and
have the minimum number of free antibodies on the EM grids.
Transmission electron microscopy
For TEM of whole bacteria, 100–200ml of PBS was added to the
blood agar growth plate and agitated gently to delicately remove
bacteria from the agar. The plate was tilted and an aliquot of the
resulting bacterial suspension was removed from close to the liquid
surface. Small aliquots of this stock suspension were then directly
loaded onto carbon-coated Parlodion microscopy grids. The
bacteria were allowed to settle (5 min) and then stabilised by
addition of 2% paraformaldehyde (40 s). Grids were washed on
droplets of water, negatively stained and examined. As dictated by
grid quality, the stock was sometimes centrifuged gently for several
minutes (3000 r.p.m. for 5–10 min), the pellet was then gently
resuspended in PBS and grids were prepared; if necessary these
steps were repeated.
Samples of the isolated pili were diluted in buffer as required and
adsorbed for 1 min to glow discharged 400 mesh carbon-coated
Parlodion or STEM grids (see below). These were washed and
negatively stained with 2% (w/v) uranyl acetate (UAc) or 2% (w/v)
phosphotungstic acid (PTA) and imaged with a CM 100 transmis-
sion electron microscope (Philips, Eindhoven, the Netherlands)
operating at 80 kV. Electron micrographs where recorded with a
2000 by 2000 pixel, charge-coupled device camera (Veleta; Olympus
soft imaging solutions GmbH, Mu¨nster, Germany) at a nominal
magnification of  130 000, yielding a final pixel size corresponding
to 0.36 nm on the specimen scale. Particles were manually selected
for single-particle analysis and averaged using the EMAN software
(Ludtke et al, 1999).
Scanning TEM
Samples were prepared on glow-discharged, thin carbon films
coating a perforated carbon layer on gold-coated copper grids,
washed and either freeze-dried for mass measurement or negatively
stained as above. Mass measurements were performed on pilus and
recombinant RrgA–His samples as described (Broz et al, 2007),
except that the grids were washed on eight drops of quartz double-
distilled water. Images were recorded from the TIGR4 pili at doses
ranging from 400 to 950 electrons/nm2 and from pili of the TIGR4
DrrgA mutant at a dose of 700±56 electrons/nm2, and evaluated
using the MASDET program package (Krzyzˇa´neka et al, 2009).
A linear regression describing the dose dependence of the mass-per-
length values determined for the former sample defined beam-
induced mass-loss. Both the TIGR4 data set and the DrrgA pilus data
were corrected accordingly and scaled to the mass-per-length
determined in the same run for tobacco mosaic virus (TMV).
Images were recorded from the RrgA–His sample at a dose of
1170±100 electrons/nm2 and evaluated using MASDET (Krzyzˇa´neka
et al, 2009). Beam-induced mass-loss was corrected according to
the behaviour of proteins in the mass range 120–190 kDa (Mu¨ller
and Engel, 2001 and unpublished results) and the data were scaled
according to the mass-per-length measured for TMV. The corrected
data sets were binned into histograms and described by Gauss
curves.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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Prevalence of pilus-encoding islets among
acute otitis media Streptococcus
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Abstract
We evaluated the distribution of the two known Streptococcus
pneumoniae pilus encoding islets (PI-1 and PI-2) among a panel of
113 acute otitis media clinical isolates from Israel. PI-1 was present
in 30.1% (n = 34) of the isolates tested, and PI-2 was present in
7% (n = 8). In addition, we found that: (i) the PI positive isolates,
50% of which belong to the international clones Spain9V-3 (ST156)
and Taiwan19F-14 (ST236), correlate with the genotype (as deter-
mined by multilocus sequence typing) but not with the serotype;
(ii) PI-2 was not present in the absence of Pl-1; and (iii) the
frequency of PI-1 was higher among antibiotic-resistant isolates.
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The human pathogen Streptococcus pneumoniae is commonly
associated with invasive diseases such as meningitis and
sepsis. In addition, pneumococci are the most frequent cause
of upper respiratory infections such as sinusitis and acute
otitis media (AOM), which is one of the most widespread
childhood infections and a major cause of morbidity in chil-
dren [1,2]. Hence, it is important to investigate the presence
of pathogenic factors that may be responsible for disease
outcome among AOM clinical isolates.
Recently, genetic analysis of S. pneumoniae clinical isolates
demonstrated that they harbour pilus structures encoded by
the rlrA pathogenicity islet (pilus islet-1, PI-1) and the pilus
islet-2 (PI-2). The PI-1 pilus was shown to be involved in
virulence [3,4] and antibodies raised against its protein
subunits were protective in a murine model of infection [5].
However, the islets are not widely distributed in S. pneumo-
niae. Three independent studies demonstrated that, in both
invasive and nasopharyngeal clinical isolates, the frequency
of the PI-1 islet is approximately 30% [6–8], although the
incidence was higher among antibiotic-resistant clones [8].
This suggests that the interplay between the pilus (encoded
by PI-1) and antibiotic resistance may facilitate the global
spread of antibiotic nonsusceptible pneumococci [9]. A
recent study demonstrated that PI-2 is present in approxi-
mately 16% of invasive and nasopharyngeal clinical isolates
[10], and that both islets are present in the Taiwan19F-14
(ST236) clone, whose spread is responsible for the increas-
ing incidence of antibiotic-resistant isolates in many coun-
tries [11–13].
Therefore, to evaluate a possible correlation between
AOM and the presence of PIs, we aimed to assess the preva-
lence of the pilus encoding islets in a collection of AOM clin-
ical isolates, for which no data are available thus far.
A total of 113 pneumococcal isolates were obtained from
the middle ear fluid of 113 patients with AOM presenting at
the Soroka University Medical Center Pediatric Emergency
Department, from 1 January 2007 to 29 March 2007. The
patients were Jewish children (n = 55) and Bedouin children
(n = 58) who did not receive the heptavalent conjugate
pneumococcal vaccine (PCV7) because PCV 7 vaccination
was not implemented in Israel at the time of the study. The
age of the children was in the range 0.8–96.9 months
(mean ± SD 13.3 ± 15.5 months; median 9.7 months). Of
the 113 isolates, 85 (75%) were obtained by tympanocentesis
and 17 (15%) were from spontaneous drainage; it was not
clear whether the remaining 11 isolates (10%) were obtained
from tympanocentesis or spontaneous drainage. Of 107 iso-
lates from which information about antibiotic treatment of
the patient in the month prior to culture was available, 32
(30%) were from children receiving antibiotics in previous
months. S. pneumoniae was isolated as a single pathogen in
62/113 (65%) cases; in 46 (41%) together with Haemophilus
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influenzae; and in five (4%) together with other combinations
of pathogens. Identification, serotyping and antimicrobial
susceptibility testing was performed as described previously
[14].
The most commonly isolated serotype was serotype 14,
followed by 19F, 23F, 19A, 6B and 18C (Fig. 1a). All isolates
were tested for the presence of PI-1 and PI-2 by PCR using
a specific set of primers as described previously [8,10].
Amplifications to determine the genomic location and the
presence of islets were performed directly from bacterial
colonies grown overnight on blood-agar plates.
Of 113 isolates, 34 (30.1%) were positive for S. pneumo-
niae PI-1 and eight (7%) were positive for PI-2; PI-1 was
found in serotypes 6A, 6B, 14, 19F, 23F, 33A and 11A,
(Fig. 1a). On the other hand, PI-2 was only found in serotype
19F isolates and always associated with PI-1 (Fig. 1a). Subse-
quently, the isolates containing PI-1 or both PI-1 and PI-2
were typed by multilocus sequence typing [15] and grouped
by E-BURST analysis (http://eburst.mlst.net/) by clonal com-
plex (CC) (Fig. 1b), revealing that they belonged to CCs
already reported to be most likely to carry the PI-1 [6–8].
Isolates that harboured both pilus islets were mainly of the
CC271, single or double locus variants of the international
clone Taiwan19F-14. Among the isolates containing only PI-1,
CC156 was the prevalent clone (international clone Spain9V-3).
Interestingly, out of 12 CC156 isolates, 11 (92%) were sero-
type 14, confirming the increasing association of this sero-
type with clone CC156 [9].
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FIG. 1. Acute otitis media (AOM) isolates collection characterized for the presence of pilus islet (PI)-1 and PI-2. (a) Collection of AOM isolates
stratified by serotype and analysed for the presence of PI-1 and PI-2. *Serotypes with two isolates only (3, 4, 8, 15B, 16F, 18A, 33A) or one iso-
late only (7B, 9N, 9V, 11A, 23A, 23B, 24F, 31, 33F, 35B, not typable). PI-1 was present only in one of the two serotype 33A isolates and in the
11A isolate. (b) PI-1 and PI-2 positive isolates stratified by clonal complex (CC), determined by E-BURST grouping, after multilocus sequence
typing. The serotypes to which the CCs are associated are shown with different colours. CCs have been named according to the sequence
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No correlation was found with age or gender of the chil-
dren, whereas the percentage of PI positive isolates among
the Jewish population was higher (43.6%) compared with
to Bedouins (17.2%), although the proportion of antibiotic
resistant clones was comparable in the two groups. More-
over, children who had experienced one or more otitis
media episodes in the previous year were more likely to be
infected with S. pneumoniae carrying the pilus-encoding islets
than children who had not (46% vs. 18%; p 0.002). The con-
comitant presence of H. influenzae in the infection site did
not correlate with PIs positive S. pneumoniae (28%).
Because PI-1 was found mainly in serotypes with prevalent
antibiotic resistance, we analysed its presence or absence by
the antibiotic-resistance pattern in each of the serotypes in
which it was described (Table 1). The percentage of PI-1
positive isolates among antibiotic-resistant strains reached
41.5% in penicillin-nonsusceptible isolates (MIC >0.1 mg/L),
51.8% among multidrug-resistant isolates, and 51.6% in eryth-
romycin- resistant isolates. By contrast, the proportion of
PI-1 strains in strains susceptible to all tested antibiotics was
5.7% (p 0.001). These findings confirm the previously found
association between piliated S. pneumoniae and antibiotic
resistance [8].
In conclusion, the data obtained in the present study indi-
cate that the incidence of piliated pneumococci in otitis
media isolates is not greater than in other invasive disease
isolates and that the pilus does not appear to confer an addi-
tional selective benefit in the middle ear during otitis media.
A limitation of the present study is the small sample size of
clinical isolates tested. However, the results obtained con-
firm the correlation of PI in S. pneumoniae with genotype and
antibiotic resistance. Further studies are needed to under-
stand the epidemiological relevance of the pilus and its role
in disease outcome. Although vaccination with PCV7
reduced the frequency of persistent and recurrent AOM
[16], multidrug-resistant nonvaccine serotypes such as sero-
type 19A are increasing, associated with CC156 [17]. This
clone was a prevalent clone in the present study. Therefore,
the elucidation of the pathogenesis of AOM may help
advance the development of a serotype-independent pneu-
mococcal vaccine for otitis media, and a new generation pro-
tein vaccine that includes pilus subunits could reduce otitis
media disease.
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Modified sequential multiplex PCR for
determining capsular serotypes of invasive
pneumococci recovered from Seville
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Abstract
The heptavalent pneumococcal vaccine’s introduction resulted in
a decline in invasive disease caused by Streptococcus pneumoniae,
but was accompanied by an increase in non-vaccine serotypes.
We evaluated a modified scheme of the sequential multiplex
PCRs adapted to the prevalence of serotypes in Seville (Spain)
for determining capsular serotypes of S. pneumoniae invasive clin-
ical isolates. In adults, the modified scheme allowed us to type
73% with the first three reactions, and 92% with two additional
PCRs. In paediatric patients, it allowed us to type 73.5% with
the first three reactions, and 90% with the two additional PCRs.
The multiplex PCR approach was successfully adapted to target
the serotypes most prevalent in Seville.
Keywords: Capsular polysaccharide, invasive infection, multiplex
PCR, serotype, Streptococcus pneumoniae
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Streptococcus pneumoniae causes severe illnesses in the
elderly and children. The immunochemistry of the capsular
polysaccharide differentiates pneumococci into 91 distinct
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